10-27-12 /revised 1

CURRICULUM VITAE Raymond Nelson DuBois, Jr.

CURRENT POSITION Executive Director of the Biodesign Institute

(December 1, 2012) Arizona State University PO BOX 875001 727 East Tyler Street Tempe, Arizona 85287 Ph (713) 745-4495 Email: <duboisrn@asu.edu>

EDUCATION AND CLINICAL TRAINING B.S. Biochemistry Texas A&M University, College Station, Texas (1977) Ph.D. Biochemistry University of Texas Southwestern Medical Center at Dallas, Texas (1981) M.D. University of Texas Health Science Center at San Antonio, Texas (1985) Osler Medicine Internship The Johns Hopkins Hospital, Baltimore, Maryland (1985-88) & Residency

Gastroenterology The Johns Hopkins Hospital, Baltimore, Maryland (1988-91)

Fellowship RESEARCH EXPERIENCE AND APPOINTMENTS July 1988-March 1991 Howard Hughes Research Associate at the Johns Hopkins School of Medicine. The aim of my research was to characterize a novel nuclear growth-activated gene (Nup 475) in Dan Nathans' laboratory. April 1991-Sept. 1994 Assistant Professor, Medicine and Cell Biology at Vanderbilt University Medical Center. Sept. 1994-Sept. 1997 Associate Professor, Medicine and Cell Biology at Vanderbilt University Medical Center. Sept. 1997-2007 Professor, Medicine & Cell Biology at Vanderbilt University Medical

Center. Feb. 1998-Jan. 2004 Director of Gastroenterology, Hepatology and Nutrition at Vanderbilt University Medical Center July 2001-2007 Professor of Cancer Biology at Vanderbilt University Medical Center Jan. 1, 2005-Feb. 2007 Director of the Vanderbilt-Ingram Cancer Center; Nashville, TN June 1, 2007-Oct 2012 Provost and Executive Vice President; Professor of Cancer Medicine

and Cancer Biology, The University of Texas MD Anderson Cancer Center Research Interests My research is focused on understanding the molecular and genetic basis

for colorectal cancer. My laboratory has several projects underway to understand the molecular mechanisms by which prostaglandins and other inflammatory mediators affect epithelial biology, the tumor microenvironment, carcinogenesis and development.

10-27-12 /revised 2

PROFESSIONAL SOCIETIES 1978 American Association for the Advancement of Science (AAAS) #00003063724

1989 American Gastroenterological Association (AGA) #157863 1991 American Society for Biochemistry and Molecular Biology (ASBMB) #154147 1991 American Association for the Study of Liver Diseases (AASLD) 1994 Southern Society for Clinical Investigation (SSCI) 1994 American Association for Cancer Research (AACR) #12959 1997 American Society for Clinical Investigation (ASCI) 1998 American Physiological Society (APS) 2000 Association of American Physicians (AAP) 2000 Royal College of Physicians (by distinction, London UK) DISSERTATION "The Induction of Cytochrome P-450 Related to Drug and Steroid Metabolism," 110 pages, The University of Texas Southwestern Medical Center at Dallas, Texas (1981). HONORS AND ACTIVITIES

Undergraduate Scholarships Sept. 1973 Houston Livestock Show & Rodeo Scholarship, National Honor Society Scholarship Graduate Training Fellowships

Sept.1979-Aug.1980 American Liver Foundation Pre-doctoral Fellow Medical School Awards

June-Aug. 1983 Robert A. Welch Foundation Fellowship for Summer Research Jan 1983 Southern Society for Clinical Investigation student abstract prize May 1985 Merck Sharp & Dohme Outstanding Medical Student Award Post Doctoral Awards

1988-1991 Howard Hughes Research Associate in Daniel Nathans’ lab Aug. 1988 NRSA "Evaluation of the Genetic Regulation for Cell Growth" IF32-DK08214 Special Honors & Awards

May 1991 American Gastroenterological Association (AGA) Industry Research Scholar March 1992 Boehringer-Ingelheim New Investigator Award April 1994 AFCR Henry Christian Award for Excellence in Research Feb. 1996 AFCR: Outstanding Invest. Award (Southern Section) Aug. 1996 American Gastroenterological Association/GRG Young Invest. Award Feb. 1997 Councilor: Southern Society for Clinical Investigation Feb. 2000 President, Southern Society for Clinical Investigation April 2000 American Federation for Medical Research: Outstanding Invest. Award April 2000 E.V. Newman Research Prize; Vanderbilt Univ. Department of Medicine May 2000 President, Gastroenterology Research Group of the AGA Nov. 2000 Royal College of Physicians (by distinction), London UK April 2002 AACR-Richard and Hinda Rosenthal Foundation Cancer Research Award July 2003 Board of Directors, American Association for Cancer Research Aug. 2003 NIH MERIT Grant Award R37-DK47297-11 (2004-2012) Dec. 2003 University of Chicago; Norman Frankel Visiting Scholar Award March 2004 Dorothy P. Landon-AACR Cancer Research Prize May 2004 AGA Distinguished Achievement Award Sept. 2004 Fellow, American Association for the Advancement of Science July 2006 Anthony Dipple Carcinogenesis Award, Oxford University Press March 2007 President, American Association for Cancer Research May 2007 The Johns Hopkins University Society of Scholars

Aug. 2010 President, International Society for Gastrointestinal Cancer Aug 2011 Catedra Gonzalo Rio Arronte Award, Mexico City, Mexico

10-27-12 /revised 3

Vanderbilt Medical Center Activities/Committees 1992-1996 Vanderbilt Clinical Nutrition Research Unit Grant Review Committee 1993-2007 Investigator: The Vanderbilt-Ingram Cancer Center 1994-2002 Investigator: Vanderbilt Molecular Toxicology Center 1994-2003 Medical Scientist Training Program (M.D./Ph.D.) Selection Committee 1994-1995 Vanderbilt-Ingram Cancer Center Faculty Search Committee Dec. 1996 Vanderbilt University Research Council Awards Committee, appointed by the Dean of the Graduate School 1996-2007 Executive Committee for the Vanderbilt Cancer Center Jan. 1997-1999 Vanderbilt University Medical Center Awards and Recognition Committee, appointed by the Vice Chancellor of Health Affairs April 1996-Dec. 2004 Director-Cancer Prevention Program Vanderbilt-Ingram Cancer Center March 1996-Nov. 1996 Chairman-Vanderbilt University Medical Center Strategic Planning Committee on Evaluating Basic Research in Clinical Departments Oct. 1996-Aug. 1997 Chairman-Vanderbilt Cancer Center search committee for cancer prevention faculty 1996-1997 Director of Research Training-Gastroenterology Division, Vanderbilt University Medical Center Nov. 1997 Cardiology Chief Search Committee-Vanderbilt University Medical Center Jan. 1998 Co-Chairman-Faculty Compensation and Incentive Committee-Vanderbilt

University Medical Center Feb. 1998 Pharmacology Chair Search Committee- Vanderbilt University Medical

Center Aug. 1998-Dec. 2004 Associate Director of the Vanderbilt-Ingram Cancer Center for Cancer Prevention and Control. Feb. 1998-Jan. 1999 Cell Biology Chair Search Committee-Vanderbilt University Medical Center July 1999 Vanderbilt-Meharry Alliance Task Force on basic science research. April 2000 Chairman-Department of Medicine Task Force Committee on Basic Research Aug. 2001-2007 Chair, Vanderbilt School of Medicine Tenure and Promotions Committee June 2002-2003 Vanderbilt School of Medicine Admissions Committee Jan. 2005-Feb. 2007 Director; The Vanderbilt-Ingram Cancer Center The University of Texas MD Anderson Activities/Committees/Honors 2007-present Chairman of the Research Council Committee-UT MD Anderson Cancer

Center 2007-present Chairman of the University Cancer Foundation Committee-UT MD

Anderson Cancer Center 2007-2011 Presidents Advisory Board-UT MD Anderson Cancer Center 2007-present Chairman of the Technology Task Force-UT MD Anderson Cancer Center 2007-2011 Executive Management Committee-UT MD Anderson Cancer Center 2008-present Ellen F. Knisely Distinguished Chair in Colon Cancer Research 2008-2011 MD Anderson Campaign Executive Committee, exceeded $1.2 Billion goal 2011-present Institutional Clinical Executive Committee, UT MD Anderson Cancer Center 2012-present Co-chair, Institutional Research Executive Committee, UT MD Anderson

Cancer Center

Research Grants & Contracts Awarded May 1991-April 1994 American Gastroenterological Association Industry Research Scholar Award $25,000/yr. x 3 yrs May 1991-April 1996 Lucille P. Markey Research Award $50,000/yr. x 4 yrs Jan. 1992 NIH Pilot Project Award for studies on the “Nutritional Modulation of Gene Expression in the Gastrointestinal Tract” $16,000/yr. x 1 yr. March 1992-Feb. 1994 Boehringer-Ingelheim New Investigator Award $26,000/yr. x 2 yrs July 1992-June 1996 VA Research Associate Career Development Award salary x 4 yrs

10-27-12 /revised 4

July 1992-June 1994 A.B. Hancock Cancer Research Award $25,000/yr. x 2 yrs Oct. 1992-Oct. 1996 VA Merit Review Grant Recipient $50,000/year x 4 yrs July 1993-June 1996 NIH PO1DK38226 Program Project Recipient (Project #4) “Eicosanoids and Renal Function.” $76,000/year x 3 yrs.(direct costs) Aug. 1994-July 1998 NIH RO1DK47297 “Role of Eicosanoids in Intestinal Epithelial Growth and Function” $124,429/year x 4 yrs ($656,000 total costs). Sept.1996-Aug. 1999 NIH N01-CN-65118 “Phase I Multiple-dose Safety and Efficacy Clinical Study of Nonsteroidal Anti-Inflammatory Based Regimens” $198,000 x 2 years.

Sept. 1996-Oct. 2001 VA Merit Review Grant “Transgenic Models to Evaluate the Role of Cyclooxygenase-2 in Colorectal Cancer” $110,000 per year x 5 years

Aug. 1998-July 2003 NIH RO5DK47297 (PI: Ray DuBois) “Role of Eicosanoids in Intestinal Epithelial Growth and Function” $188,429/year (direct costs) x 5 yrs.

May 1997-April 2001 NIH NO1-CN-65239 “Phase I Multiple -dose Study on Chemoprevention of Colorectal Cancer in HNPCC Patients” $156,000 x 2 years.

Feb. 1999-Jan. 2004 NCI P01 CA77839 (PI: Ray DuBois). “Mechanisms for Progression of Colorectal Cancer,” Total direct funding $5,030,371.

April 1999-Feb. 2003 NO1-CN-85083-57 (CO-PI: Ray DuBois). “Phase II Clinical Studies of Chemopreventive Agents,” Total Direct Funding $20, 203,100, PI Monica Bertagnolli, Cornell-Strang Cancer Center, NY.

July 1997-June 2007 T32 DK07673-09 (PI: Ray DuBois) Training in Gastroenterology, $130,000 per year for 5 years (direct costs).

June 2002-May 2005 NIH P30DK58404 (PI: Ray DuBois) Molecular and Cellular Basis for Digestive Diseases, 700,000 per year for five years (direct costs)

Jan. 2005-July 2007 NCI P30 CA068485 (PI: Ray DuBois). Vanderbilt Cancer Center Support Grant, Total direct funding $25,357,775.

June 2002-May 2012 NIH RODK62112 (PI: Ray DuBois) Nuclear Hormone Receptors and Intestinal Epithelial Biology $250,000 per year for 5 years (direct costs).

Aug. 2003-July 2014 NIH R37-DK47297 MERIT GRANT (PI: Ray DuBois) “Role of Eicosanoids in Intestinal Epithelial Growth and Function” $250,000 per year x 10 years (direct costs).

Feb. 2004-Jan. 2011 NCI P01 CA77839 (PI: Ray DuBois). “Mechanisms underlying early neoplasia,” Total direct funding $5,540,371.

Aug 2002-Aug 2013 U54 CA096300-07 (CoPI: Ray DuBois). “Partnership for excellence in Cancer Research with the University of Puerto Rico,” $4,139,205

April 2010-April 2013 RP 100960 (PI: Ray DuBois) Cancer Prevention and Research Institute of Texas, “Prostaglandins and Inflammation in Colorectal Cancer,” $1,200,000

May 2012-Jan. 2017 NCI P01 CA77839 (PI: Ray DuBois). “The role of bioactive lipids in inflammation and cancer,” Total funding awarded $6,020,000.

June 2010-May 2013 RP 101502 (PI: Ray DuBois) Cancer Prevention and Research Institute of Texas, Research Training Grant, $2,565,789.

PENDING

5RO1 DK062112-11 (DuBois) 09/01/2012-08/31/2017 NIH/NIDDK $273,000 Nuclear Hormone Receptors in Intestinal Biology

RP100960 (DuBois)

6/1/2013-5/31/2016

Cancer Prevention & Research Institute of Texas (CPRIT)

$490,947

Prostaglandins and Inflammation in Colorectal Cancer

Other Outside Activities May 1991-1999 John Sealy Memorial Endowment Fund Advisory Committee UT Medical Branch-Galveston, Texas.

10-27-12 /revised 5

Jan. 1992-1994 Volunteer Scientist for the Cumberland Science Museum in Nashville TN. March 1992-1993 Volunteer Science lecturer for the Lower School at the University School of Nashville, TN. Fall 1994-1996 Volunteer lecturer for the Vanderbilt Health Plus Program. Cancer Prevention and Screening. Dec. 11, 1995 Colorectal cancer screening call-in show. Channel 5 Television Show to increase public awareness in Middle Tennessee of colorectal cancer screening and prevention. Sept. 11, 1996 Colorectal cancer awareness meeting. Open forum for public education

on colon cancer awareness and screening, University Club, Nashville, TN, Keynote speaker--former Governor of Tennessee, Ned McWherter.

May 1, 1998 Career Opportunities in Biomedical Sciences. Speaker in a forum held at Vanderbilt University Medical Center for presenting career opportunities to scientists and physicians in training at Vanderbilt and Meharry Medical Schools.

June 5, 1998 Vanderbilt-Ingram Cancer Center Retreat. Speaker in session on “Enzymes: Basic Frontiers & Clinical Targets,” Cyclooxygenase-2: A target for Cancer Prevention. March 4, 2000 Colorectal cancer screening call-in show. Channel 5 Television Show to increase public awareness in Middle Tennessee of colorectal cancer screening and prevention. Dec. 6, 2000 Colorectal cancer awareness call-in show. Channel 5 Television Show to answer questions from citizens in Middle Tennessee of colorectal cancer screening and prevention.

Feb. 2003 Dissertation Opponent, Kirsi Saukkonen, Ph.D., Molecular and Cancer Biology Research Program, University of Helsinki, Finland.

PATENTS USSN 6,448,000; “Mammalian Genes Involved in Viral Infection and Tumor Suppression

TEACHING & MENTORING RESPONSIBILITIES

1991-1992 Lecturer Molecular Oncology Course for Cell Biology Department

1991-1993 Director Department of Medicine Research Colloquium. Dissertation Committee Member for the following graduate students:

Cell Biol. Dept.: Mike Jones (Ph.D. 6/93), Al Candia (Ph.D. 8/94), Kathy Hepner (Ph.D. 3/97), Allen Adams (Ph.D. 8/98), Jamie Collins in the Mol. Phys. Dept.(Ph.D. 12/94), Asit Parikh, Biochemistry (Ph.D. 8/98), Larry Bischof, Biochemistry (Ph.D. 9/98), Zoe Brown, Biochemistry (Ph.D. 6/00), Victor Soukoulis (Ph.D.2/05), Cell and Developmental Biology, Li Yang (Ph.D.6/05), Cancer Biology, Chad Johnson (Ph.D.), Cancer Biology, Rebecca Dise (Ph.D. 3/06), Cell & Developmental Biology, Ann Ru (Ph.D. 2/06), Cell & Developmental Biology.

Phase I Committee Member for Nancy Wall, Brenda McAdory, Tom Polte, Lori Rudolph, Ute Priglinger, Kim Lickteig, Laura Kuo, Reade Roberts and Renee Ireton in the Cell Biology Department. 1991-2000 Department of Medicine Attending, Vanderbilt Hospital/VA Hospital. 1991-2000 GI Ward Service for Nashville VA Hospital, 2 months/yr. 1993-1994 Preceptor-Stephen Bailey and Walter Hurt; Biomedical Research Elective. 1993-1995 Organizer and Lecturer for the Molecular Gastroenterology Section of the Interdepartmental Graduate Program Course. 1995-1996 Lecturer-Cell Biology Departmental Course for graduate students. 1995-1998 Gastrointestinal Physiology Section of the medical physiology course, 1st year Medical Students (7 lecture hours). 1997-1998 Interdepartmental Graduate Program Molecular Basis of Disease lectures. March 1996 Medicine Grand Rounds Vanderbilt University Medical Center; Concepts in Colorectal Cancer Prevention: “Does an aspirin a day really keep the

10-27-12 /revised 6

cancer away?” July 1996 Vanderbilt University Medical Scientist Training Program Retreat Keynote Address, “Future Challenges for Biomedical Research as We Approach the Next Millennium,” Paris Landing State Park, TN. Feb. 1997-1998 Cancer Biology 342 Course--section on programmed cell death. Feb. 1998 Medicine Grand Rounds Vanderbilt University Medical Center; Molecular mechanisms for prevention of cancer. April 2000 Medicine Grand Rounds Vanderbilt University Medical Center; Cyclooxygenase and colorectal cancer prevention. Jan. 2004-2006 Cell and Developmental Biology, CB 338 Special Topics in Cell and Developmental Biology. NATIONAL COMMITTEES & ACTIVITIES 1994-1997 AASLD Abstract Selection Committee for Morphology, Cancer and Liver Regeneration Section. 1996-1998 AGA Abstract Selection Committee for GI Oncology. 1994-1997 FASEB Congressional Liaison Committee. 1994-1995 AACR Membership Committee May 1995 Organizer & Chairman for AGA Research Symposium on Eicosanoids and Colorectal Cancer, Annual AGA meeting, San Diego, CA. 1995 Point and Counterpoint in Digestive Diseases, National Update in Colorectal Cancer Screening and Molecular Genetics. Dearborn, MI, Oct. 21 1995. San Francisco, CA, Nov. 11, 1995. 1996 Issues and Answers in Digestive Diseases, Chairman of Session on Update in Digestive Diseases (Teleconference). The Maxwell Regency Hotel, Nashville, TN, Oct. 5, 1996. May 1997-1998 American Federation for Medical Research Public Policy Committee, ad hoc member. June 1998-2001 National Cancer Institute Chemoprevention Implementation Committee. July 1998-present Executive Committee Aspen Cancer Conference, Aspen CO. July 1999-present Board of Directors, Aspen Cancer Foundation, Aspen CO. Jan. 14, 1999 NCI Cancer Prevention Strategic Planning Committee, The William Bolger Center, Potomac, MD. April 1999 Organizer, for the Keystone Conference on Molecular Mechanisms for Gastrointestinal Cancer, Keystone, CO, April 1-7, 1999. April 1999 Organizer, for AACR Cancer Prevention Symposium at the annual AACR meeting, Philadelphia, PA, April 10-14, 1999. May 1999-2003 Vice-Chair & Chair of the GI Onoclogy Section; American Gastroenterological Association Council. June 1999-present Scientific Advisory Board of the Keystone Symposia on Molecular and Cellular Biology.

July 1999-present National Colorectal Cancer Research Alliance Foundation, Founding member Scientific Board. Executive directors are Katie Couric and Lilly Tartikoff. The goal of this alliance is to raise private funding for colorectal cancer research and increase public awareness/screening for the disease.

July 1999-June 2000 Co-Chair NCI Colon Cancer Progress Review Group. Appointed by the Director of the NCI to develop the strategy for key areas of colorectal cancer research for the next decade. Oct. 2000 Special Advisory Board, Mayo Clinic Cancer Center, Rochester, MN. May 2000 Chairman-American Gastroenterological Association (AGA) Nominating Committee. Dec. 2000-2006 Scientific Advisory Board Member; Glaxo Institute of Digestive Health. Dec. 2000-2006 External Advisory Board Member. MD Anderson Cancer Center Program Project Grant on “The impact of smoking on lung cancer prevention.” PI: W. Ki Hong Nov. 2001-present Board of Directors for the Keystone Symposium on Molecular and Cellular

Biology

10-27-12 /revised 7

Jan. 2001 Co-Organizer, for the Keystone Conference on Molecular Medicine for Colorectal Cancer, Taos, NM, Jan. 30-Feb. 4, 2001. March 2001 Chairperson, Mini-symposium on Gastrointestinal Malignancies: Biology and

Treatment; AACR Meeting, New Orleans, LA. May 2001 Chair of ASCO symposium on colorectal cancer prevention. March 2001-2004 External Advisory Board Member, University of Maryland Cancer Greenbaum

Center, Baltimore, MD. April 2001 Program Co-Chairperson, 93rd Annual American Association for Cancer

Research Meeting, San Francisco, CA. April 2001 External Advisory Board Member. Johns Hopkins Gastrointestinal Cancer

SPORE. PI: Scott Kern. April 2001 External Advisory Board Member. UCSF Liver Cancer SPORE. PI: Monty

Bissell Jan. 2002 Member-American Gastroenterological Association (AGA) Nominating

Committee June 2002-2006 Member-American Gastroenterological Association (AGA) Research Policy

Committee Oct. 2002-03 Program Chair, 2nd AACR International Conference on “Frontiers in Cancer

Prevention Research.” Phoenix, AR. Nov. 2002-2005 National Cancer Institute: Board of Scientific Advisors to the Director Feb. 2003-2006 NIDDK Advisory Council Member (NIH) April 2003-2007 External Advisory Board Member, Washington University Digestive Disease

Research Center, St. Louis, MO. May 2003 Co-chair of the AGA Sponsored GI Division Chiefs Workshop. Dec. 2003 External Review Panel for the Department of Medicine (Gastroenterology

Division), University of Pennsylvania, Philadelphia, PA. June 2004-2006 Chairman, Board of Directors, Keystone Symposia on Molecular and Cellular

Biology, Silverthorne, CO. July 2004-July 2006 External Advisory Board Member, University of Cincinnati Cancer Center,

Cincinnati, OH. June 2004-present External Advisory Board Member. University of North Carolina-Chapel Hill GI

Cancer SPORE. PI: Joel Tepper. 2004-2007 Member; AACR Special Conferences Committee.

2004-2006 Member, Board of Directors for the American Association of Cancer Research. Oct. 2005 Co-Chair, AACR meeting on Colorectal Cancer: Molecular Pathways and New

Therapies. 2005-2007 Member; AACR Publications Committee. April 2006 Program Co-Chairperson, 97th Annual American Association for Cancer Research

Meeting, Washington, DC. June 2006 Chairman, The Jeannik M. Littlefield-AACR Grants in Colorectal Cancer Review

Committee. June 2006-2007 Chairman, External Advisory Committee, San Antonio Cancer Institute, University

of Texas Health Science Center, San Antonio, TX. 2005-present Member; AACR Science Policy and Legislative Affairs Committee. 2007 Co-chair; AACR 2007 Colorectal Cancer Conference, Boston, MA. 2006-2008 External Advisory Board Member: The Cancer Institute of New Jersey, Robert

Wood Johnson Medical School, New Brunswick, NJ. 2006-present Medical Advisory Board Member; Cancer Research and Prevention Foundation,

Alexandria, VA. 2007 Howard Hughes Medical Institute Physician Scientist selection committee. 2009-present Member: Science and Prevention Advisory Council for the Cancer Prevention and

Research Institute of Texas, Austin, TX. 2009-present External Advisory Board Member, Ohio State University (The James)

Comprehensive Cancer Center, Columbus, OH. INTERNATIONAL COMMITTEES 1996-1997 World Health Organization Advisory Committee to examine world colorectal

cancer chemoprevention policy.

10-27-12 /revised 8

Sept.1997-May 1999 International Study Group for Clinical Indications of Cyclooxygenase-2 Inhibitors.

Sept. 12-14, 1997 First International Workshop on Cyclooxygenase-2. Steering Committee Member. New Orleans, LA.

July 27-31, 1998 Second International Workshop on Cyclooxygenase-2. Steering Committee Member. Maui, HI.

Sept. 1999-Sept. 2000 Chairman: International Study Group on Cyclooxygenase-2. EDITORIAL DUTIES

1996-2004 Associate Editor: Apoptosis June 1996 Guest Editor: Gastroenterology Clinics of North America. July 1997-2000 Editorial Board: Am J Physiology: GI &Liver Phys. July 2002-2008 Editorial Board: Am J Physiology: GI &Liver Phys. Jan. 1998-2000 Editorial Board: Carcinogenesis Jan. 2007-2009 Editorial Board: Carcinogenesis Jan. 2007-present Associate Editor Clinical Translational Sciences Jan. 1998-present Editorial Board: Neoplasia Jan. 1999-present Editorial Board: Clinical Cancer Research June 2000-2008 Associate Editor Cancer Research July 2001-2006 Editorial Board: J. Biol. Chem. Aug. 2001-2006 Associate Editor: Gastroenterology Aug. 2003-2008 Associate Editor: Prostaglandins & Other Lipid Mediators TRAINEES 1991-1994 Phyllis Bishop, M.D., pediatric GI fellow, preceptor for research training. Assoc. Prof. Pediatrics, University of Mississippi Medical Center, Jackson, MS.. 1991-1993 Yue-Sheng Wu, M.S. degree in Cell Biology. Now a Research Associate at the Bronx VA in New York, NY.. 1991-1994 Chris Schmidt, Undergraduate Molecular Biology work study student Completed M.D. degree at the University of Cincinnati School of Medicine. 1993-1994 Charles Eberhart, M.D., GI fellow, preceptor for research training Now a practicing gastroenterologist in Vero Beach, FL. 1992-1995 M. Tsujii, M.D., Ph.D., Postdoctoral Fellow. Now an Assistant Professor at Osaka University Medical School, Osaka, Japan. 1993-1994 David Myers, MSII, One year research project. American Heart Association student fellow. Completed training in Pediatrics at U. Michigan. 1995-1997 Osamu Kobaysashi, M.D., Postdoctoral Fellow. Now a Research Scientist at Juntendo University, Tokyo, Japan. 1995-1997 Lynn Sanderson, M.A.degree in Cell Biology. 1996-1998 Jeff Brockman, Ph.D., Postdoctoral Fellow. 1995-1999 Christopher Williams. M.D./Ph.D., Now an Assist. Prof. of Medicine and Cancer

Biology at Vanderbilt University, Nashville, TN. 1997-2002 Rajnish Gupta, M.D./Ph.D., Now a Clinical Assist. Prof. of Dermatology at

Stanford University, Palo Alto, CA. 1998-1999 Hiroaki Murata, M.D., Postdoctoral Fellow. 1998-2004 Zhonghua Zhang, M.D., Postdoctoral Fellow. 1998-1999 Moss Mann, M.D., Honor's medical student research project. 1999-2000 Gideon Hanekom, Ph.D., Postdoctoral Fellow, Currently an Assistant Professor in the Department of Immunology, Groote Schuur Hospital, University of Cape Town, South Africa. 2001-2006 Greg Buchanan, Ph.D., Research Assistant Professor. 2001-2002 Marco Turini, Ph.D., Visiting Scholar from Nestec Research Institute, Lusanne, Switzerland. 2001-2002 Woong Chang, M.D., Ph.D., Postdoctoral Fellow. 2001-2002 Masahiro Yoshinaga, M.D., Postdoctoral Fellow. 2001-2003 Koga Komatsu, M.D., Ph.D., Postdoctoral Fellow.

10-27-12 /revised 9

2002-present Dingzhi Wang, Ph.D., Research Associate Professor. 2003-2005 JoAnn Brown, Ph.D., Postdoctoral Fellow. 2003-present Vijay Holla, Ph.D., Research Assistant Professor. 2003-2006 Yong Cha, M.D./Ph.D., student. 2003-2006 Jason Mann, M.D./Ph.D., student.

2003-2004 Dagny Sandnes, Ph.D., Visiting Professor from University of Oslo, Norway. 2003-2005 Yuko Kino, M.D., Postdoctoral Fellow. 2004-2007 Michael Backland, Ph.D., Postdoctoral Fellow. 2006-2007 Nikki Bush, Interdisciplinary Graduate Program student. 2006-present Dianren Xia, Postdoctoral Fellow. 2007-present David Menter, Research Assistant Professor. 2007-present Sun Hee Kim, Postdoctoral Fellow. 2010-present Yuchen Du, Postdoctoral Fellow. 2011-present Hiroshi Katoh, Postdoctoral Fellow. 2011-present Ofer Margalit, Postdoctoral Fellow. 2011-present Zhi Wen, Postdoctoral Fellow.

National Symposia and Invited Presentations (selected) Oct.1993 Invited speaker, Eicosanoids and Cancer, Georgetown University, Washington, DC. April 1994 Invited speaker for “New Approaches to Cancer Therapy” Johns Hopkins Oncology

Center, Baltimore, MD. Sept. 1994 University of Michigan Cancer Center Grand Rounds, Eicosanoids and Colorectal

Cancer: “Is there a link?” Ann Arbor, MI. Jan. 1995 GI Grand Rounds. St. Luke’s-Roosevelt Center, College of Physicians and Surgeons of Columbia University, New York, NY. Oct. 1995 Invited speaker, Michigan State University, Department of Biochemistry, East Lansing, MI,. Oct. 1995 Invited speaker, University of Michigan, Department of Medicine; Division of

Gastroenterology, Ann Arbor, MI. Oct. 1995 Invited speaker, NIEHS, “Colorectal Cancer Prevention and NSAIDs,” Research

Triangle Park, N.C. Nov. 1995 Visiting Professor, Department of Medicine/Gastroenterology Division, The University of Chicago Hospitals and Clinics, Chicago, Il. March 1996 Invited speaker, Department of Medicine/Gastroenterology Division, The Johns Hopkins School of Medicine, Baltimore, MD. March 1996 Invited speaker, “Symposium on GI Cancers: Biology and Genetics,” American Gastroenterological Association, Reston, VA. Sept. 1996 Invited speaker, Crohn’s & Colitis Foundation meeting on “Immune-Non Immune Cell Interactions in Intestinal Inflammation,” Tampa, FL. Jan. 1997 Invited speaker, Keystone Symposia on “Recent Advances in Lipid Mediators,” Keystone, CO. Jan. 1997 Invited speaker, Digestive Diseases Center, Yale University School of Medicine,

New Haven, CT. Jan. 1997 Visiting Professor, James H. Quillen College of Medicine, East Tennessee State University, “The Molecular Medicine Lecture Series,” Johnson City, TN.

10-27-12 /revised 10

March 1997 Visiting Professor, Gastroenterology Unit, MGH, Harvard School of Medicine, Boston, MA.

March 1997 Invited speaker, University of Virginia Cancer Center, Charlottesville, VA. April 1997 Invited speaker, National Cancer Institute,“Colorectal Cancer Prevention: Is

Cyclooxygenase-2 a Potential Target?” Bethesda, MD. May 1997 Medical Grand Rounds and GI Grand Rounds, “Current Concepts in Colorectal Cancer Prevention,” University of Alabama, Birmingham, AL. June 1997 Invited speaker, FASEB Summer Conference on “Cytokines and Lipid Mediators,”

Saxtons River, VT. July 1997 Medical Grand Rounds & Boyer Center Research Seminar, Yale University Medical

Center, New Haven, CT. July 1997 Invited speaker, Aspen Cancer Conference, Aspen, CO. Aug. 1997 Visiting Professor, Department of Medicine/Gastroenterology Division, Duke University Medical Center, Durham, NC. Sept. 1997 Visiting Professor, Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS. Oct. 1997 Invited speaker, Coldspring Harbor Symposium on “Immunological Attacks on Cancer,” Banbury Center, Cold Spring Harbor, NY. Feb. 1998 Invited speaker, “Novel Therapeutic Targets for the Treatment of Colon Cancer,” Memorial Sloan-Kettering Cancer Symposium, New York, NY. Feb. 1998 Invited speaker, “Prostaglandin-Mediated Cellular Proliferation: The Role of Cyclooxygenase-2 in Non-Inflammatory Processes,” New York Academy of Sciences, New York, NY. March 1998 Irwin C. Vinnik Lectureship, “Mechanisms for Colorectal Cancer Prevention” The University of Colorado Heath Sciences Center, Denver, CO. May 1998 Invited speaker for Cancer Prevention Workshop at the American Society of Clinical Oncology meeting, Los Angeles, CA. Aug. 1998 Invited speaker, Gordon Research Conference, “New Insights into the Molecular Genetics of Cancer,” Colby-Sawyer College, NH. Oct.1998 Invited speaker, 51st Annual Symposium of Fundamental Cancer Research, MD Anderson Cancer Center, Houston, TX. Nov.1998 Invited speaker, Strang-Cornell International Cancer Prevention Conference, “Novel

Nutrient & Pharmaceutical Developments,” New York, NY. Nov. 1998 Zetzel Visiting Professor, Harvard Digestive Disease Center, Beth Israel Deaconnes Medical Center, Boston, MA. Jan. 28, 1999 Invited speaker, University of Alabama-Birmingham Cancer Center ,Birmingham,

AL. March 10, 1999 Medicine Grand Rounds Speaker, New York University Medical Center, New York,

NY. April 28, 1999 John V. Carbone Distinguished Lecturer, UCSF Department of Medicine and Cancer Center, San Francisco, CA.

10-27-12 /revised 11

June 2-3, 1999 Visiting Lecturer for the Digestive Disease Section and Medicine Grand Rounds speaker, University of Illinois at Chicago, Chicago, IL. July 1999 Invited speaker, Gordon Conference on Novel Experimental Therapeutics for Cancer Treatment and Prevention, New London, NH. July 1999 Organizing Committee and Session Chairman, 14th Annual Aspen Cancer Conference, Aspen, CO. Sept. 1999 Invited speaker, “New Horizons in Cancer Prevention,” Roswell Park Cancer Institute, Buffalo, NY. Sept. 1999 Invited speaker, University of Texas Southwestern Medical Center, University Lecture Series, Dallas, TX. Nov. 1999 Invited speaker, Annual Meeting for the American Society of Nephrology, “Update on COX-1 and COX-2 Inhibitors,” Miami, FL. Dec. 1999 Invited speaker, “Update in Topics for Gastroenterology,” Columbia University, New York, NY. Feb. 2000 Guest Professor, Graduate Course in Molecular Medicine, University of Texas Institute for Biomedicine, San Antonio, TX. May 2000 James C. Respess Visiting Professor, University of Virginia, Charlottesville, VA. Sept. 2000 Invited Speaker, “Overview of Colorectal Cancer Screening for Primary Care Physicians,” The Jewish Hospital, Louisville, KY. Jan. 2001 Invited Speaker, Keystone Symposia on “The Molecular Medicine of Colorectal Cancer,” Taos, NM. Feb. 2001 Grand Rounds Speaker, UT MD Anderson Cancer Center, Houston, Texas. March 2001 Invited Speaker, Symposium on “Colon Cancer: The Molecular View,” AACR

meeting, New Orleans, LA.

April 2001 Invited Speaker, Harvard Digestive Diseases Symposium on “Epithelial Biology and Colorectal Cancer,” Boston, MA.

May 2001 Chairman of Scientific Symposium on “The Role of COX-1 and COX-2 Inhibitors in

Carcinogenesis,” ASCO Meeting, San Francisco, CA. May 2001 Invited speaker, “Cancer and the Environment: Gene Environment Interactions,”

Institute of Medicine, The National Academies, Washington, DC. June 2001 Visiting Professor, UCLA Division of Digestive Diseases & CURE, Los Angeles, CA.

Oct. 2001 Chairman and Invited Speaker, AACR-NCI-EORTC 2201 “Mol Targets and Cancer

Therapeutics: Discovery, Biology and Clinical Applications,” Miami Beach, FL. Feb. 2002 American Association for Cancer Scientific Retreat: “New Frontiers in Cancer

Research,” led by Phil Sharp, Boston, MA. April 2002 The Richard and Hinda Rosenthal Foundation Award Lecture. American

Association for Cancer Research Meeting, San Francisco, CA Aug. 2002 Speaker, 21st Summer Symposium in Molecular Biology, “Xenobiotic Receptors in

Toxicology and Carcinogenesis,” Penn State University, State College, PA.

10-27-12 /revised 12

Octo. 2002 Invited Speaker, NCI-DOE Imaging Workshop to evaluate new cancer targets for imaging, San Diego, CA.

Oct. 2002 Invited Speaker, First International Colorectal Congress, Palm Beach, FL. March 2003 Invited Speaker, Keystone Symposia on “Eicosanoid Lipid Mediators: From

Molecular Discovery to Clinical Application,” Tahoe City, CA. March 2003 Invited Speaker, Keystone Symposia on “Molecular Targets for Cancer Therapy,”

Banff, Canada. April 2003 Invited Speaker, Medical Grounds Rounds, GI Grand Rounds, Oncology Grand

Rounds, Emory University Medical Center, Atlanta, GA. May 2003 Keynote Address, Johns Hopkins School of Medicine, Department of Medicine

Research Retreat, Applied Physics Laboratory, Columbia, MD. June 2003 The Roger S. Mitchell Lecture, "Eicosanoids in Lung Carcinogenesis and

Chemoprevention," The Thomas L. Petty Aspen Lung Conference, Aspen, CO. Oct. 2003 Invited Speaker; AACR Meeting on Angiogenesis & Cancer, Chicago, IL. Dec. 2003 The Normal Frankel Visiting Scholar of the University of Chicago, Chicago, IL. Feb 2004 Invited Speaker; Department of Medicine, Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO. March 2004 The Dorothy P. Landon Cancer Prize Lecture, AACR Meeting, Orlando, FL. April 2004 Invited Speaker, Department of Pharmacology, Johns Hopkins School of Medicine,

Baltimore, MD. May 2004 The AGA Distinguished Achievement Award Lecture, American Gastroenterological

Association Meeting, New Orleans, LA. June 2004 Visiting Professor in Gastroenterology, Department of Medicine, Brigham and Women’s

Hospital, Harvard Medical School, Boston, MA. Sept. 2004 Woodward Visiting Professor, Department of Medicine, Memorial Sloan-Kettering

Cancer Center, New York, NY. Oct. 2004 Claire and Jack Nath Memorial Lecture, Massachusetts General Hospital, Harvard

School of Medicine, Boston, MA. Oct. 2004 Invited speaker, Jackson Labs Symposium on Intestinal Cancer, Bar Harbor, ME. March 2005 John Walsh Distinguished Lecturer, CURE Digestive Disease Research Center,

UCLA School of Medicine, Los Angeles, CA. Feb. 2005 8th Annual Petros A. Palandjian Visiting Professor, Dana Farber Cancer Center,

Harvard School of Medicine, Boston, MA. Dec. 2005 42nd Annual Martin E. Rehfuss Lecture, Thomas Jefferson University,

Philadelphia, PA.

Feb. 2006 Medical Grand Rounds, Department of Medicine, Columbia University School of Medicine, New York, NY.

Feb. 2006 Keynote Speaker, NIH Workshop on Inflammation and Gastrointestinal Cancer,

National Cancer Institute, Bethesda, MD.

10-27-12 /revised 13

Feb. 2006 Distinguished Lecturer, National Institute of Environmental Health Sciences,

Research Triangle Park, NC. Feb. 2006 Scientific Address, NIDDK Advisory Council, NIH, Bethesda, MD. July 2006 Invited Speaker, GI Oncology Division, MD Anderson Cancer Center, Houston, TX. July 2006 Public Address: “Cancer Prevention, What the Public Should Know?,” Aspen

Cancer Conference, Aspen Institute, Aspen, CO. Aug.2006 Invited Speaker, San Antonio Cancer Institute, University of Texas Health Science

Center, San Antonio, TX. Oct. 2006 Gerald N. Wogan Lecture, Division of Biological Engineering, Massachusetts

Institute of Technology, Cambridge, MA. Feb. 2007 Keynote Address, AACR Special Conference on Advances in Proteomics in

Cancer Research, Amelia Island, FL. June 2007 1st Annual Dan L. Duncan Lecture, Baylor College of Medicine, Dan L. Duncan

Cancer Center, Houston, TX. Oct. 2007 Keynote Address, Annual Society for Leukocyte Biology Meeting, Boston, MA. Jan. 2008 Keynote Address, Keystone Meeting on ”Eicosanoids and Other Mediators of

Chronic Inflammation,” Big Sky, Montana. Jan. 2008 Keynote Address, 1st Annual Cullen Translational Research Symposium,

University of Texas Graduate School of Biomedical Sciences, Houston, TX. Jan. 2008 The Blaffer Lecture, The University of Texas MD Anderson Cancer Center,

Houston, TX. Jan. 2008 The Mike Hogg Distinguished Lecture, The University of Texas MD Anderson,

Smithville Research Park, Smithville, TX. Jan. 2009 Invited Speaker, Keystone Symposia on “Angiogenesis and Cancer,” Big Sky,

Montana. Feb. 2009 The Allen and Lee Chao Lecture and Visiting Professorship in Cancer

Research, The University of California at Irvine, Irvine, CA. April 2009 Joint AACR/ASCO Symposium on COX-2 and Cancer Treatment, “COX-2 and

Cancer Biology, Denver, CO. May 2009 The Englert Distinguished Lecture, The University of Utah, Salt Lake City, Utah. July 2009 The Ben Trump Lecture, Aspen Cancer Conference, Aspen, CO. July 2009 Jason Morrow Memorial Research Symposium, “Prostaglandins and Cancer,”

Vanderbilt University Medical Center, Nashville, TN. Dec. 2009 The Daniel G. Miller Endowed Lecture, “Inflammation and Cancer Progression,”

Cornell-Weill Medical Center, New York, NY. Oct. 2010 Invited Speaker, Jackson Labs Colon Cancer Research Conference, Bar Harbor,

ME. Nov. 2010 Invited Speaker, AACR Colon Cancer Research Conference, Philadelphia, PA.

10-27-12 /revised 14

Jan. 2011 Keynote address, International Society for Gastroenteric Cancer, Houston, TX. March 2012 Keynote address, Ohio State University Cancer CenterAnnual Scientific Meeting,

Columbus, OH June 2012 Invited Speaker, The Biodesign Institute, Arizona State University, Tempe AZ September 2012 Hauck Visiting Professorship, The Mayo Clinic Cancer Center, Rochester MN

International Symposia and Invited Presentations (selected) April 1994 Keynote speaker, Japan Digestive Disease Week, Kobe, Japan, Plenary Session. June 1996 Session Chairman, The International Symposium on “Evolving strategies for Managing NSAID Use,” Stockholm, Sweden. June 1996 Invited speaker, Molecular Medicine Seminar Series, The University of Nottingham, Nottingham, United Kingdom. June 1996 Invited speaker, Paterson Institute for Cancer Research and the Christie Hospital, Manchester, United Kingdom. Sept. 1996 Invited speaker, 10th International Conference on Prostaglandins and Related Compounds, Vienna, Austria.

Oct. 1996 Keynote speaker, Japan Gut Club, Tokyo, Japan. Oct. 1996 Invited speaker, First International Conference on Gastroenterological Carcinogenesis, Hiroshima, Japan. Oct. 1996 Invited speaker, Osaka University, First Department of Medicine, Osaka, Japan. Feb. 1997 Invited speaker, Ninth Annual Lorne Cancer Conference, Lorne, Australia. March 1997 Invited speaker, International William Harvey Research Conference on “Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential,” Cannes, France. Sept. 1997 Plenary speaker and Session Chairman, 5th International conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases,” LaJolla, CA. Nov.1997 Invited speaker, The Peter MacCallum Cancer Institute Symposium, “New strategies for cancer detection and therapy,” Melbourne, Australia. Feb. 1998 Invited speaker, US-Japan Cancer Workshop, Kona, Hawaii. April 1998 Invited speaker, International William Harvey Research Conference on Clinical Relevance of Selective COX-2 Inhibitors, Boston, MA. June 1998 Invited speaker, NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands. Sept. 1998 Invited speaker. Japanese Inflammation Society. Keio International Hotel, Tokyo, Japan.

10-27-12 /revised 15

Oct. 1998 Invited speaker. Falk Symposium #110 on Epithelial Differentiation. Titisee, Germany. Feb.1999 Invited speaker, Ninth International Congress on Anti-Cancer Treatment, Palais des Congres, Paris, France. April 1999 Keynote speaker, 11th International Taisho Symposium on Gastroenterology, Shimoda, Japan.

June 1999 Invited speaker, Royal College of Physicians Conference on Treatment and Prevention of Colorectal Cancer, London, UK. July 1999 Invited speaker, Mount Carmel Colorectal Cancer Conference, Haifa, Israel. Aug. 1999 Invited speaker, Canadian Digestive Disease symposium on Clinical Applications for COX-2 Inhibitors, Vancouver, British Columbia. Sept. 1999 Invited speaker and Session Co-Chair for the 6th International conference on “Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases,” Boston, MA. Oct. 1999 Invited speaker and Session Chairman, International William Harvey Research Conference on Selective COX-2 Inhibitors, Lisbon, Portugal. March 2000 State of the Art Lecture on Colorectal Carcinogenesis, Canadian Digestive Disease Week, Quebec City, Canada. May 2000 Invited Speaker, McGill Colon Cancer Conference, Montreal, Canada. June 2000 Invited Speaker and Session Chairman, 11th International Conference on Advances in Prostaglandin and Leukotriene Research, Florence, Italy. Oct. 2000 Invited Speaker and Session Chairman, William Harvey Research Conference on "Defining the Role of COX-2 Inhibitors in Inflammatory and Other Diseases,” Porto, Portugal. Oct. 2000 Invited Speaker. Third Annual SAS International Molecular Medicine Symposium, Isle of Crete, Greece. Nov. 2000 The 25th Annual William Harvey Lecture, The William Harvey Research

Institute, Charterhouse Square, London, UK Dec. 2000 Invited speaker, 2nd Annual CARE Symposium on Gastrointestinal Cancer, Hong Kong, China. Jan. 2001 Invited speaker, International Symposia on Cyclooxygenase-2 and Disease, Tokyo, Japan. June 2001 Invited speaker, 5th Annual US—Japan Joint Conference on Gastrointestinal Cancer, Tokyo, Japan. Sept. 2001 Invited speaker, AACR International Conference Seoul 2001, “Molecular Mechanisms of Gastrointestinal Cancer Development and Its Clinical Implications,” Seoul, South Korea. Sept. 2002 Invited Speaker, First Annual International Symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, The Netherlands.

Jan. 2003 Invited Speaker, Fifth International Symposium on Anti-Angiogenic Agents, San Diego, CA.

10-27-12 /revised 16

Feb. 2003 Invited speaker, Biomedicum Helsinki, University of Helsinki, Frontiers in Medicine Seminar Series, Helsinki, Finland.

June 2003 Invited speaker, Emerging Issues on Digestive Cancer Prevention, Bologna, Italy. Sept. 2003 Keynote speaker, 4th Annual Montreal Colon & GI Cancer Conference, McGill

Cancer Centre, Montreal, Canada. March 2004 Invited speaker, British Society of Gastroenterology, Glasgow, Scotland, UK. June 2004 Invited speaker, Annual ISOBM Meeting, Helsinki, Finland. Sept. 2004 Invited speaker, UEGW Symposium on GI Malignancies, Prague, Czech Republic. Oct. 2004 Invited Speaker, European Society of Medical Oncology, Vienna, Austria. Aug. 2005 Invited Speaker, Young Investigator Mentoring Symposia, Tokyo, Japan. Oct.2005 Invited Speaker, Falk Symposium 149 on GI Cancer, Berlin, Germany. Jan. 2006 Invited Speaker, Osaka University Medical Center & Kitano Medical Research

Institute & Hospital Symposium, Osaka, Japan. July 2006 Anthony Dipple Award Lecture, European Association for Cancer Research,

Budapest, Hungary. June 2007 Kyoto University COE Symposium, Kyoto, Japan. June 2007 Barcelona Biomedical Conference, Inflammation and Chronic Disease, Barcelona,

Spain. Sept. 2007 Insubria International Summer School on Colorectal Cancer, Varese, Italy. Nov. 2007 Chairman and Invited Speaker, 38th Annual Princess Takamatsu Research

Symposium on Colorectal Cancer, Tokyo, Japan. Nov. 2008 Invited Speaker, 18th Annual Hiroshima Cancer Symposium, Hiroshima, Japan. Nov. 2008 Keynote Speaker, “Global Oncology: Challenges and Opportunities”; National

Healthcare Group (NHG) Scientific Congress, Singapore. March 2009 Invited Speaker, Kyoto University/ MD Anderson Symposium on Cancer

Research, Kyoto, Japan. Nov. 2009 Keynote Speaker, “Inflammation and Cancer,” Chinese Medical University/MD

Anderson Cancer Symposium, Taichung, Taiwan.

August 2011 Keynote Speaker, Catedra Gonzalo Rio Arronte Award Ceremony, Mexico City, Mexico

Feb 2012 Keynote Address, Center for Medical and Scientific Innovation, The University of

Tokyo, Tokyo, JAPAN Reviewer Granting Agencies NIEHS Small Business Contracts Review, 1994-1995. UTMB John Sealy Memorial Endowment Fund, 1993-1997. Veterans Administration; Spring 95 (GI Merit Review Committee). NCI, Cancer Prevention Research Unit Review, March 1996.

10-27-12 /revised 17

NIH GMA2 Study Section, 6/96, 10/98, 2/99 (7/99-8/02). NCI, Program Project Review for NCI, Nov. 1996. NCI, Master’s Agreement Review Committee, Aug. 1997. Research Grants Council (RCG) of Hong Kong, Aug. 2002. Cancer Research UK, Aug. 2002. Journal Reviewer Cell; Cancer Cell; Nature, Nature Med., Science, Journal of Clinical Investigation;

J. Biol. Chem., Proc. Natl. Acad. Sci. (USA); Gastroenterology; Hepatology; Cancer Res.; FASEB J.; Genes and Development; Development; Mol. Pharm.; Journal Natl. Cancer Inst., Carcinogenesis, Neoplasia, NEJM, JAMA, Lancet.

BIBLIOGRAPHY Research Publications

1. DuBois R.N. and Waterman M.R. (1979) "Effect of Phenobarbital Administration to Rats on the

Level of in vitro Synthesis of Cytochrome P-450 Directed by Total Rat Liver RNA," Biochem. Biophys. Res. Commun., 90, 150-157.

2. DuBois R.N., Simpson E.R., Lambeth J.D., Tuckey J. and Waterman M.R.(1981) "Evidence for a

Higher Molecular Weight Precursor of Cholesterol Side Chain Cleavage Cytochrome P-450 and Induction of Mitochondrial and Cytosolic Proteins by Corticotropin in Adult Bovine Adrenal Cells," Proc. Natl. Acad. Sci. USA., 78, 1028-1032.

3. DuBois R.N., Simpson E.R., Kramer R.E. and Waterman M.R. (1981) "Induction of Synthesis of

Cholesterol Side Chain Cleavage Cytochrome P-450 by ACTH in Cultured Bovine Adrenocortical Cells," J. Biol. Chem., 256, 7000-7005.

4. John M.E., DuBois R.N. and Waterman M.R. (1981) "Altered Heme Environments in Opossum

and Rabbit Methemoglobins," Zeitschrift fur Naturforschung, 36, 964-967. 5. Kramer R.E., DuBois R.N., Simpson E.R., Anderson E.M., Kashiwagi K., Lambeth J.D., Jefcoate

C.R. and Waterman M.R. (1982) "Cell-Free Synthesis of Precursor Forms of Mitochondrial Steroid Hydroxylase Enzymes of the Bovine Adrenal Cortex," Archives of Bioch. & Biophys., 215, 478-485.

6. DuBois R.N., Hill K.E. and Burk R.F. (1983) "The Antioxidant Effect of Acetaminophen on Liver,"

Biochem. Pharm., 32, 17, 2621-2622 7. DuBois R.N., Lazenby A.J., Yardley J.H., Hendrix T.R., Bayless T.M. and Giardiello F.M. (1989)

"Lympho Entero-Colitis in Patients with 'Refractory Sprue,'" JAMA, 262, 935-937. 8. DuBois R.N., McLane M., Ryder K., Lau L.F., and Nathans D. (1990) “A Growth factor inducible

nuclear protein with a novel cysteine/histidine repetitive sequence,” J. Biol. Chem. 265, 19185-19191.

9. Holt P.R. and DuBois R.N. (1991) “In vivo Immediate Early Gene Expression Induced in Intestinal

and Colonic Mucosa by Feeding”, FEBS Letters, 287, 102-104. 10. Capdevila J.H., Wei S., Yan J., Karara A., Jacobson H.R., Falck J.R., Guengerich F.P. and

DuBois R.N. (1992) “The Cytochrome P-450 Arachidonic Acid Epoxygenase: Regulatory Control of the Renal Epoxygenase by Dietary Salt Loading,” J. Biol. Chem., 267, 21720-21726.

11. Karara A., Makita K, Jacobson H.R., Falck J.R., Guengerich F.P., DuBois R.N., and Capdevila

J.H. (1993) “Molecular Cloning, Expression and Characterization of a Rat Kidney Cytochrome P450 Arachidonic Acid Epoxygenase,” J. Biol. Chem., 268, 13565-13570.

12. Collins J.F., Honda T., Knobel S., Bulus N.M., Conary J., DuBois R.N. and Ghishan F.K. (1993)

“Molecular Cloning, sequencing, tissue distribution, and functional expression of a Na+/H+ Exchanger (NHE-2),” Proc. Natl. Acad. Sci. USA., 90, 3938-3942.

10-27-12 /revised 18

13. Barnard J.A., Graves-Deal R., Pittelkow, M.R., DuBois R.N., Cook, P., Ramsey, G.W., Bishop, P. R., Damstrup L. and Coffey R.J. (1994) “Auto- and Cross-induction within the Mammalian Epidermal Growth Factor-related Peptide Family,” J. Biol. Chem., 269, 22817-22822.

14. DuBois R.N., Tsujii M., Bishop P., Awad J.A., Makita, K. and Lanahan A. (1994) “Cloning and

Characterization of a Growth Factor Inducible Cyclooxygenase Gene from Rat Intestinal Epithelial Cells,” Am. J. Physiol., 226 (29), G6822-G6827.

15. DuBois R.N., Awad J., Roberts J., Morrow J. and Bishop P. (1994) “Regulation of Eicosanoid

Production and Mitogenesis in Rat Intestinal Epithelial Cells by TGFα and Phorbol Ester,” J. Clin. Invest. 93, 493-498.

16. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S. and DuBois R.N. (1994)

“Upregulation of Cyclooxygenase-2 Gene Expression in Human Colorectal Adenomas and Adenocarcinomas,” Gastroenterology, 107, 1183-1188.

17. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., DuBois R.N. and Breyer M.D. (1994)

“Cyclooxygenase-2 is associated with the macula densa in rat kidney and increases with salt restriction,” J. Clin. Invest., 94, 2504-2510.

18. Capdevila J.H., Morrow J.D., Belosludtsev Y.Y., Beauchamp R.C., DuBois R.N. and Falck J.R.

(1995) “The Catalytic Outcomes of the Constitutive and the Mitogen Inducible Isoforms of Prostaglandin H2 Synthetase are Markedly Affected by Glutathione and Glutathione Peroxidase(s),” Biochemistry, 34, 3325-3337.

19. DuBois R.N., Bishop P., Graves-Deal R., Coffey, R.J. (1995) “TGFα Regulation of Two Zinc

Finger Containing Immediate Early Response Genes in the Intestine.” Cell Growth and Differentiation, 6, 523-529.

20. Giardiello F.M., Offerhaus G.J.A. and DuBois R.N. (1995) “The Role of Nonsteroidal Anti-

inflammatory Drugs in Colorectal Cancer Prevention.” European Journal of Cancer, 31, 1071-1076.

21. Zelden D.C., DuBois R.N., Falck J.R. and Capdevila J.C. (1995) “Molecular Cloning, Expression

and Characterization of an Endogenous Human Cytochrome P450 Arachidonic Acid Epoxygenase Isoform,” Archives of Biochemistry, 322, 76-86.

22. Tsujii M. and DuBois R.N. (1995) “Alterations in Cellular Adhesion and Apoptosis in Intestinal

Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase-2,” Cell, 83, 493-501.

23. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., DuBois R.N., Clark R., Ague M. and Schreiber R.D. (1996) “Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the Jak-Stat signaling pathway,” Cell, 84, 431-442.

24. DuBois R.N., Shao J., Sheng H., Tsujii M. and Beauchamp R.D. (1996) “G1 Delay in Intestinal

Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase-2 (COX-2),” Cancer Res., 56, 733-737.

25. DuBois R.N., Radhika A., Reddy B.S., Entingh A.J. (1996) “Increased Cyclooxygenase-2 Levels

in Carcinogen-Induced Rat Colonic Tumors,” Gastroenterology, 110, 1259-1262. 26. Williams C.S., Luongo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp, R.D. and

DuBois R.N. (1996) “Elevated Cyclooxygenase-2 Levels in Min Mouse Adenomas.” Gastroenterology, 111, 1134-1140.

27. Zhang T., Nanney L., Luongo C., Lamps L., Heppner K.J., DuBois R.N. and Beauchamp R.D.

(1997) “Concurrent Overexpression of Cyclin D1 and Cyclin-dependent Kinase 4 (Cdk4) in Intestinal Adenomas from Multiple Intestinal Neoplasia (Min) Mice and Human Familial Adenomatous Polyposis Patients,” Cancer Res. 57, 169-175.

10-27-12 /revised 19

28. Schmedtje J.F., Ji Y.S., Liu W.L., DuBois R.N. and Runge M.S. (1997) “Hypoxia induces Cyclooxygenase-2 via the NF-κB p65 Transcription Factor in Human Vascular Endothelial Cells,” J. Biol. Chem. 272, 601-608.

29. Coffey R.J., Hawkey C.J., Damstrup L., Graves-Deal R., Daniel V.C., Dempsey P.J., DuBois

R.N., Jetton T. and Morrow J. (1997) “EGF receptor activation induces nuclear targeting of COX-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells,” Proc. Natl. Acad. Sci. USA, 94, 657-662.

30. Watson A.J.M. and DuBois R.N. (1997) "Lipid metabolism and APC: implications for colorectal

cancer prevention," Lancet, 349, 444-445. 31. Sheng H., Shao J., Hooten E.B., Tsujii M., DuBois R.N. and Beauchamp, R.D. (1997)

“Cyclooxygenase-2 induction by TGFβ in rat intestinal epithelial cells,” Cell Growth and Differentiation, 8, 463-470.

32. Guan Y.F., Chang M., Cho W.Y., Zhang Y.H., Redha R., Davis L., Chang S., DuBois R.N., Hao C-

H. and Breyer M. (1997) “Cloning, Tissue Distribution and Renal Expression of Cyclooxygenase-2,” Am. J. Phys., 273, F18-F26.

33. Zhang T., Nanney L., Peeler M.O., Williams C.W., Lamps L., Heppner K.J., DuBois R.N. and

Beauchamp R.D. (1997) “Decreased TGFβ Type II Receptor Expression in Intestinal Adenomas from Min/+ Mice is Associated with Increased Cyclin D1 and Cdk4 Expression,” Cancer Res. 57, 1638-1643.

34. Tsujii M., Kuwano S. and DuBois R.N. (1997) “Cyclooxygenase-2 Expression in Human Colon

Cancer Cells Increases Metastatic Potential,” Proc. Natl. Acad. Sci. USA, 94, 3336-3340. 35. Sheng H., Shao J., Kirkland S., Isakson P., Coffey R., Morrow J., Beauchamp, R.D. and DuBois

R.N. (1997) “Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2,” J. Clin. Invest., 99, 2254-2259.

36. Sheng G.H., Shao J., Sheng H., Hooton E.B., Coffey R.J., DuBois R.N. and Beauchamp R.D.

(1997) “A selective cyclooxygenase-2 inhibitor (SC-58125) suppresses the growth of H-Ras transformed rat intestinal epithelial cells,” Gastroenterology, 113, 1883-1891.

37. Williams C.S., Smalley W. and DuBois R.N. (1997) “Aspirin Use and Potential Mechanisms for

Colorectal Cancer Prevention,” J. Clin. Invest., 100, 1325-1329. 38. Chang M., Tsai J.C., Tang R., DuBois R.N., Breyer M.D. and O’Day D. (1997) “Induction of

Rabbit Cyclooxygenase-2 in the Anterior Uvea Following Glaucoma Filtration Surgery,” Current Eye Research, 16, 1147-1151.

39. Sheng G.H., Shao J., Morrow J., Beauchamp, R.D. and DuBois R.N. (1998) “Modulation of

Apoptosis by Prostaglandin Treatment in Human Colon Cancer Cells,” Cancer Res., 58, 362-366. 40. DuBois R.N., Gupta R., Reddy B.S., Krakow S.L and Lazar M.A. (1998) “The Nuclear Eicosanoid

Receptor, PPARγ, is Aberrantly Expressed in Colonic Cancers,” Carcinogenesis, 19, 49-53. 41. Giardiello F.M., Spannhake E.W., DuBois R.N., Hylind L.M., Majewski J. L., Hubbard W.C.,

Hamilton S.R. and Yang V.W. (1998) “Prostaglandin levels in human colorectal mucosa: effect of sulindac on familial adenomatous polyposis patients,” Dig. Diseases and Sciences, 43, 311-316.

42. Sheng H., Shao J., Williams C.S., Pereira M.A., Taketo M.M., Oshima M., Reynolds A.B.,

Washington M.K., DuBois R.N. and Beauchamp R.D. (1998) “Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas,” Carcinogenesis 19, 543-549.

43. Tsujii M., Kawano S.,Tsuji S., Sawaoka H., Hori M. and DuBois R.N. (1998) “Cyclooxygenase

Regulates Angiogenesis Induced by Colon Cancer Cells,” Cell, 93, 705-716.

10-27-12 /revised 20

44. Sheng H., Williams C.S., Shao J., Liang P., DuBois R.N. and Beauchamp R.D. (1998) “Induction of Cyclooxygenase-2 by activated Ha-ras in Rat-1 Fibroblasts and the role of the MAPK pathway,” J. Biol. Chem., 273, 22515-22518.

45. Goldman A.P., Williams C.S., Sheng H., Lamps L.W., Williams V.P., Pairet M., Morrow J.D. and

DuBois R.N. (1998) “Meloxicam inhibits the growth of colorectal cancer cells,” Carcinogenesis, 19, 2195-2199.

46. Ethridge R.T., Hellmich M.R., DuBois R.N. and Evers M.B. (1998) “Inhibition of heat shock

protein-70 induction in intestinal cells overexpressing Cyclooxygenase-2,” Gastroenterology, 114, 1454-1463.

47. Brockman J.A., Gupta R.A. and DuBois R.N. (1998) “Activation of PPARγ Leads to Inhibition of

Anchorage Independent Growth of Human Colorectal Cancer Cells,” Gastroenterology, 115, 1049-1055.

48. Karnes W.E., Shattuck-Brandt R., Burgart L.J., DuBois R.N., Tester D.J., Cunningham J.M., Kim

C.Y., McDonnell S.K., Schaid D.J., and Thibodeau S.N. (1998) "Reduced COX-2 protein in colorectal cancer with defective mismatch repair,” Cancer Res., 58, 5473-5477.

49. Lipsky L.P.E., Abramson S.B., Crofford L., DuBois R.N., Simon L.S. and van de Putte L.B.A.

(1998) “The classification of cyclooxygenase inhibitors,” J. Rheumatol., 25, 2298-2303. 50. Sheng H., Shao J., O’Mahony C.A., Lamps L., Albo, D., Isakson P.C., Berger D.H., DuBois R.N.

and Beauchamp R.D. (1999) “Chronic TGF-β treatment causes malignant transformation of rat intestinal epithelial cells,” Oncogene, 18, 855-867.

51. Shao J., Sheng H., Radhika A., Pereira M.A., Lubet R., Hawk E., Grogan L., Lamps L., Kirsch I.,

Washington .K, Beauchamp R.D. and DuBois R.N. (1999) “Coordinate Regulation of Cyclooxygenase-2 and TGF-β1 in Hereditary Nonpolyposis Colorectal Cancer and Azoxymethane-Induced Rat Colonic Tumors,” Carcinogenesis, 20, 185-191.

52. Shattuck-Brandt R.L., Lamps L.W., Heppner Goss K.J., DuBois R.N. and Matrisian, L.M. (1999)

“Matrilysin and cyclooxygenase-2 are differentially expressed in intestinal and colorectal neoplasms,” Mol. Carcinogenesis, 24, 177-187.

53. Williams C.S., Goldman A.P., Sheng H., Morrow J.D. and DuBois R.N. (1999) "Sulindac sulfide,

but not sulindac sulfone, inhibits the growth of colon cancer cells,” Neoplasia, 1, 170-176. 54. Lim H., Gupta R.A., Paria B.C., Moller D.E., Morrow J.D., DuBois R.N., Trzaskos J.M. and Dey

S.K. (1999) “Cyclooxygenase-2 derived prostacyclin mediates embryo implantation in the mouse via PPARδ,” Genes and Development, 13, 1561-1574.

55. Hideki K., Ikawa H., Hsi L.C., Watanabe T., DuBois R.N. and Eling T.E. (1999) "Regulation of 12-

Lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis by butyrate," Arch. Biochem. & Biophys. 368, 45-55.

56. O'Mahony C.A., Beauchamp R.D., Albo D., Tsujii M., Sheng H., Shao J., DuBois R.N. and Berger

D.H. (1999) "Cyclooxygenase-2 alters transforming growth factor-β1 response during intestinal tumorigenesis," Surgery 126, 364-370.

57. Shattuck-Brandt R.L., Varilek G.W., Radhika A., Yang F., Washington M.K. and DuBois R.N.

(2000) “Cyclooxygenase-2 expression is increased in the subepithelial myofibroblasts of colon and cecal carcinomas from IL-10 (-/-) mice,” Gastroenterology 118, 337-345.

58. Zhang Z. and DuBois R.N. (2000) "Par-4, a pro-apoptotic gene, is regulated by NSAIDs in human

colon cancer cells," Gastroenterology 118, 1012-1017. 59. Sheng H., Shao J., Dixon D.A., Williams C.S., Prescott S.M., DuBois R.N. and Beauchamp R.D.

(2000) "Transforming growth factor-beta1 enhances Ha-ras-induced expression of

10-27-12 /revised 21

cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA," J. Biol. Chem. 275, 6628-6635.

60. Shao J., Sheng H., DuBois R.N. and Beauchamp R.D. (2000) "Oncogenic Ras-Mediated Cell

Growth Arrest and apoptosis is associated with increased ubiquitin-dependent cyclin D1 degradation," J. Biol. Chem., 275, 22916-22924.

61. Williams C.S., Tsujii, M., Reese J., Dey S.K. and DuBois R.N. (2000) "Host cyclooxygenase-2

modulates carcinoma growth," J. Clin. Invest. 105, 1589-1594.

62. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L., Levin B., Godio L., Patterson S., Rodriguez-Bigas M.A., Jester S.L., King K.L., Schumacher M., Abbruzzese J., DuBois R.N., Hittelman W.H., Zimmerman S., Sherman J.W. and Kelloff G. (2000) "The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis," N. Engl. J. Med. 342:1946-1952.

63. Callejas N.A., Bosca L., Williams C.S., DuBois R.N. and Martin-Sanz P. (2000) "Regulation of

Cyclooxygenase-2 Expression in Hepatocytes by CCAAT/Enhancer-Binding Proteins," Gastroenterology 119, 493-501.

64. Shao J., Sheng H., Inoue H., Morrow J.D. and DuBois R.N. (2000) “Regulation of Constitutive

Cyclooxygenase-2 Expression in Colon Carcinoma Cells," J. Biol. Chem. 275, 33951-33956.

65. Williams C.S., Watson A.J.M., Sheng H., Helon R., Shao J. and DuBois R.N. (2000) "Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models," Cancer Res. 60, 6045-6051.

66. Gupta R.A., Tan J., Krause W.F., Geraci M.F., Willson T.M., Dey S.K. and DuBois R.N. (2000)

“Prostacyclin-mediated activation of PPARδ in colorectal cancer," Proc. Natl. Acad. Sci. USA 97, 13275-13280.

67. Zhang Z., Sheng H., Shao J., Beauchamp R.D. and DuBois R.N. (2000) "Post-transcriptional

regulation of cyclooxygenase-2 in rat intestinal epithelial cells," Neoplasia 2, 523-530. 68. Tong B.J., Tan J., Tajeda L., Das S.K., Chapman J.A., DuBois R.N. and Dey S.K. (2000)

"Heightened Expression of Cyclooxygenase-2 and Peroxisome Proliferator-Activated Receptor-δ in Human Endometrial Adenocarcinoma," Neoplasia 2, 483-490.

69. Kandil H., Tanner G., Smalley W., Halter S., Radhika A. and DuBois R.N. (2001)

“Cyclooxygenase-2 expression in Barrett’s esophagus,” Digestive Diseases and Sciences 46, 785-789.

70. Shappell S.B., Gupta R.A., Manning S., Whitehead R., Boeglin W.E., Schneider C., Case T., Price

J., Pack G.S., Wheeler T.M., Matusik R.J., Brash A.R., and DuBois R.N. (2001) 15-Hydroxyeicosatetraenoic acid (15-HETE) activates PPARγ and inhibits proliferation of PC3 prostate carcinoma cells, Cancer Res. 61, 497-503.

71. Souto E.O., Miyoshi H., DuBois R.N. and Gores G.H. (2001) "Kupffer cell derived

cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats," Am. J. Physiol. 280, G805-G811.

72. Sheng H., Shao J. and DuBois R.N. (2001) "Akt/PKB activity is required for Ha-Ras mediated

transformation of intestinal epithelial cells," J. Biol. Chem. 276, 14498-14504. 73. Sheng H., Shao J., DuBois R.N. (2001) “K-Ras–mediated induction of cyclooxygenase-2 involves

Akt/PKB activity," Cancer Res. 61, 2670-2675. 74. Mann M., Sheng H., Shao J., Williams C.S., Pisacane P.I., Sliwkowski M.X. and DuBois R.N.

(2001) "Targeting Cyclooxygenase-2 and HER2/Neu pathways inhibits colorectal carcinoma growth," Gastroenterology 120, 1713-1719.

10-27-12 /revised 22

75. Sheng H., Shao J., Washington M.K., DuBois R.N. (2001) “Prostaglandin E2 Increases Invasiveness of Colorectal Carcinoma Cells," J. Biol. Chem. 276, 18075-18081. 76. Zhang Z. and DuBois R.N. (2001) “Global gene expression in intestinal epithelial cells following

NSAID treatment,” Oncogene, 20, 4450-4456. 77. Gupta R.A., Brockman J.A., Sarraf P., Willson T.M. and DuBois R.N. (2001) “Target genes of

peroxisome proliferator-activated receptor gamma in intestinal epithelial cells,” J. Biol. Chem. 276, 29681-29687.

78. Gupta R.A., Polk B.P., Krishna U., Israel D.A., Yan F., Willson T.M., DuBois R.N. and Peek R.M.

(2001) “Activation of peroxisomal proliferator-activated receptor gamma suppresses NF-κB-mediated apoptosis induced by H. pylori in gastric epithelial cells,” J. Biol. Chem. 276, 31059-31066.

79. Pyo H., Choy H., Amorino G.P., Kim J.S., Cao Q., Hercules S.K. and DuBois R.N. (2001) “A

selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on cells which express cyclooxygenase-2,” Clin. Cancer Res., 7, 2998-3005.

80. Kobayashi O., Miwa H., Watanabe S., Tsujii M., DuBois R.N., Sato N. (2001) “Cyclooxygenase-2

downregulates inducible nitric oxide synthase in rat intestinal epithelial cells,” Am. J. Physiol. 281, G688-G696.

81. Reese J., Das S.K., Paria, B.C., Lim H., Song H., Matsumoto H., Knudtson K.L., DuBois R.N. and

Dey S.K. (2001) “Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation,” J. Biol. Chem., 276, 44137-44145.

82. Williams C.S., Sheng H., Brockman J.A., Armandla R., Shao J., Washington M.K., Elkahloun A.G.

and DuBois R.N. (2001) “A cyclooxygenase inhibitor (SC-58125) blocks growth of established human colon cancer xenografts,” Neoplasia 5, 428-436.

83. Shao J., Sheng H. and DuBois R.N. (2002) Peroxisome Proliferator-activated Receptors (PPARs)

modulate K-Ras-mediated Transformation of Intestinal Epithelial Cells,” Cancer Res. 62, 3282-3288.

84. Kawai N, Tsuji S, Tsujii M, Ito T, Yasumaru M, Kakiuchi Y, Kimura A, Komori M, Sasaki Y, Hayashi

N, Kawano S, DuBois R.N. and Hori M. (2002) “Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells,” Gastroenterology 122, 331-339.

85. Kozak K.R., Gupta R.A., Moody J.S., Ji C., Boeglin W.E., DuBois R.N., Brash A.R. and Marnett

L.J. (2002) “15-lipoxygenase metabolism of 2-arachidonylglycerol: Generation of a PPARα agonist” J. Biol. Chem. 277, 23278-23286.

86. Gupta R.A., Sarraf P., Brockman J.A., Shappell S.B., Raftery L.A., Willson T.M. and DuBois R.N.

(2002) “Convergence of TGFβ and PPARγ signaling pathways to regulate TSC-22 and inhibit cell growth,” J. Biol. Chem., 278, 331-339.

87. Daikoku T., Matsumoto H., Gupta R.A., Das S.K., Gassmann M., DuBois R.N. and Dey

S.K.(2002) “Expression of hypoxia-inducible factors in the periimplantation mouse uterus is regulated in a cell-specific and ovarian steroid hormone-dependent manner: Evidence for differential function during early pregnancy. J. Biol. Chem. 278, 7431-7438.

88. Wagenaar-Miller R.A., Hanley G., Shattuck-Brandt R., DuBois R.N., Bell R.L., Matrisian L.M. and

Morgan D.W (2003) “Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction” British J. Cancer, 88, 1445-1452.

89. Berger D.H., O'Mahony C.A., Sheng H., Shao J., Albo D., DuBois R.N. and Beauchamp R.D.

(2003) Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Surgery, 133, 568-579.

10-27-12 /revised 23

90. Gupta R.A., Tejada L.V., Tong B.J., Das S.K., Morrow J.D., Dey S.K. and DuBois RN (2003) “Cyclooxygenase-1 is Over-Expressed and Promotes Angiogenic Growth Factor Production in Ovarian Cancer” Cancer Res., 63, 906-911.

91. Gupta R.A., Sarraf P., Mueller E., Brockman J.A., Prusakiewicz J.J., Eng C., Willson T.M. and

DuBois R.N. (2003) “PPARγ mediated differentiation: A mutation in colon cancer cells reveals divergent and cell-type specific mechanisms,” J. Biol. Chem., 278, 22669-22677.

92. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. (2003) “Prostaglandin E2 regulates cell

migration via the intracellular activation of the epidermal growth factor receptor,” J. Biol. Chem., 278, 35451-35457.

93. Lee S.H., Williams M.V., DuBois R.N. and Blair I.A. (2003) “Targeted lipidomics using electron

capture atmospheric pressure chemical ionization mass spectrometry,” Rapid Comm. in Mass Spectrometry, 17, 2168-2176.

94. Buchanan F.G., Chang W., Sheng H., Shao J., Morrow J.D. and DuBois R.N. (2004)

“Upregulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor,” Gastroenterology, 127, 1391-1400.

95. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K. and DuBois R.N. (2004) “Activation of the

nuclear hormone receptor PPARδ accelerates intestinal adenoma growth,” Nature Medicine, 10, 245-247.

96. Yoshinaga M., Buchanan F.G. and DuBois R.N. (2004) “15-LOX-1 inhibits p21 (Cip/WAF-1)

expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells,” Prostaglandins and Other Lipid Mediators, 73, 111-122.

97. Wang D., Wang H., Shi Q., Katkuri S., Das S.K, Dey S.K. and DuBois R.N. (2004) “Prostaglandin

E2 promotes colorectal adenoma growth via transactivation of the nuclear hormone receptor peroxisome proliferator activated receptor delta,” Cancer Cell, 6, 285-295.

98. Wang H., Guo Y., Wang D., Kingsley P., Marnett L., Das S. and DuBois R.N., Dey, S.K. (2004)

“Aberrant cannabinoid signaling impairs oviductal transport of embryos,” Nature Medicine, 10, 1074-1080.

99. Organ E.L., Nalbantyan C.D., Nanney L.B., Woodward S.C., Sheng J., DuBois R.N., Price

J., Sutcliffe M., Coffey R.J. and Rubin D.H. (2004) “Effects of transforming growth factor-alpha (TGF-alpha) in vitro and in vivo on reovirus replication,” DNA Cell Biol. 23:430-441.

100. Blot W.J., Fischer T., Nielson G.L., Friis S., Mumma M., Lipworth L., DuBois R.N.,

McLaughlin J.K. and Sorensen H.T. (2004) “Outcome of upper gastrointestinal bleeding and use of ibuprofen versus paracetamol,” Pharm. World Sci. 26, 319-323.

101. Holla V.R., Wang D., Brown J.R., Mann J. and DuBois R.N. (2005) “PGE2 regulates the

complement inhibitor CD55/Decay Accelerating Factor in Colorectal Cancer,” J. Biol. Chem., 280, 476-483.

102. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L.,

Katkuri S. and DuBois R.N. (2005) “15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer,” J. Biol. Chem., 280, 3217-3223 (Epub: Nov. 12, 2004).

103. Wang D., Buchanan F.G., Wang H., Dey S.K. and DuBois R.N. (2005) “PGE2 enhances

intestinal adenoma growth via activation of the Ras-MAPK cascade,” Cancer Res., 65, 1822-1829.

104. Buchanan F.G, McReynolds M., Couvillon A., Kam Y., Holla V.R. DuBois R.N. and Exton J.H.

(2005) “Requirement of phospholipase D1 activity in H-RasV-12 induced transformation,” Proc. Natl. Acad. Sci. USA, 102, 1638-1642.

10-27-12 /revised 24

105. Cha Y., Kim S., Solnicka-Krezel L. and DuBois R.N. (2005) “COX-1 signaling is required for vascular tube formation during development,” Developmental Biology, 282, 274-283.

106. Lee S.H., Williams M.V., DuBois R.N. and Blair I.A. (2005) “Cyclooxygenase-2 mediated DNA

damage,” J. Biol. Chem., 280, 28337-28346.

107. Komatsu K., Buchanan F.G., Katkuri S., Morrow J.D., Inoue H., Otaka M., Watanabe S. and DuBois R.N. (2005) “Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated by COX-2,” Gastroenterology 129, 577-590

108. Daikoku T., Wang D., Tranguch S., Morrow J.D., Orsulic S., DuBois R.N. and Dey S.K. (2005)

“Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer,” Cancer Res., 65, 3735-3744.

109. Musiek E.S., Gao L., Milne G.L., Han W., Everhart M.B., Wang D., Backlund M.G., DuBois R.N.,

Zanoni G., Vidari G., Blackwell T.S. and Morrow J.D. (2005) “Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages.” J. Biol. Chem. 280, 35562-35570.

110. Holla V.J,. Mann J.R., Shi Q. and DuBois R.N. (2006) “PGE2 regulates the nuclear receptor

NR4A2 in colorectal cancer,” J. Biol. Chem. 281, 2676-2682. (Epub: November 17, 2005)

111. Cha Y.I., Kim S.H., Sepich D., Buchanan F.G,. Solnica-Krezel L. and DuBois R.N. (2006) “Cyclooxygenase-1 derived PGE2 promotes cell motility via the G-protein coupled EP4 receptor during vertebrate gastrulation,” Genes and Development, 20, 77-86.

112. Buchanan F.G., Gorden D.L., Matta P., Shi Q., Matrisian L.M. and DuBois R.N. (2006) “Role of

β-Arrestin-1 in the Metastatic Progression of Colorectal Cancer,” Proc. Natl. Acad. Sci. USA, 103, 1492-1497.

113. Mann J.R., Backlund M.G., Buchanan F.G., Daikoku T., Holla V.R., Rosenberg D.H., Dey S.K.

and DuBois R.N. (2006) “Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases PGE2 and promotes cancer progression,” Cancer Res. 66, 6649-6656.

114. Wang D., Wang H., Brown J., Daikoku T., Dey S.K. and DuBois RN (2006) “CXCL1 induced by

PGE2 promotes angiogenesis in colorectal cancer,” Journal of Experimental Medicine 203, 941-951, [Epub: 2006 March 27].

115. Batts L.E., Polk D.B., DuBois R.N. and Kulessa H. (2006) “Bmp signaling is required for intestinal

growth and morphogenesis.” Dev. Dyn. 235, 1563-1570, [Epub: 2006 March 14]

116. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K. and DuBois R.N. (2006) “Crosstalk between peroxisome proliferator activated receptor δ and VEGF accelerates cancer progression,” Proc. Natl. Acad. Sci. USA 103, 19069-74 [Epub: 2006 Dec 5]

117. Komatsu K., Buchanan F.G., Otaka M., Jin M., Odashima M., Horikawa Y., Watanabe S. and

DuBois R.N. (2006) “Gene expression profiling following constitutive activation of MEK 1 and transformation of rat intestinal epithelial cells,” Mol. Cancer 5, 63 [Epub 17 Nov 2006].

118. Horikawa Y., Otaka M., Komatsu K., Jin M., Odashima M., Wada I., Matsuhashi T., Ohba R.,

Oyake J., Hatakeyama N., DuBois R.N. and Watanabe S. (2007) “MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism,” Dig. Dis. Sci. 52, 2757-2765.

119. Buchanan F.G., Holla V., Katkuri S., Matta P. and DuBois R.N. (2007) “Targeting

cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer,” Cancer Res. 67, 9380-9388.

10-27-12 /revised 25

120. Daikoku T., Tranguch S., Chakrabarty A., Wang D., Khabele D., Orsulic S., Morrow J.D., DuBois R.N. and Dey S.K. (2007) “Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer,” Cancer Res. 67, 5285-5292.

121. Lee S.H., Rangiah K., Williams M.V., Wehr A.Y., DuBois R.N. and Blair I.A. (2007)

“Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-eicosatetraenoic acid by rat intestinal epithelial cells,” Chem. Res. Toxicol. 20,1665-1675.

122. Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli

W., DuBois R.N. and Dey S.K. (2007) “Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success,” J. Biol. Chem. 282, 37770-377782. [Epub 2007 Oct 26]

123. Holla V.R., Backland M.G., Yang P., Newman R.A. and DuBois R.N. (2008) “Regulation of

prostaglandin transporters in colorectal neoplasia,” Cancer Prev. Res. 2, 93-99. [Epub 2008 Mar 19]

124. Backlund M.G., Mann J.R., Holla V.R., Shi Q., Daikoku T., Dey S.K. and DuBois RN (2008)

“Repression of 15-hydroxyprostaglandin dehyrdrogenase involves histone deacetylase 2 and snail in colorectal cancer,” Cancer Res. 68, 9331-9337.

125. Wang D., Wang H., Ning W., Backlund M.G., Dey S.K. and DuBois R.N. (2008) “Loss of

cannabinoid receptor 1 accelerates intestinal tumor growth,” Cancer Res. 68, 6468-6476.

126. Pedchenko T.V., Gonzalez A.L., Wang D., DuBois R.N. and Massion P.P. (2008) “Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer,” Am. J. Respir. Cell Mol. Biol. 39, 689-696.

127. Xia D., Holla V.R,. Wang D., Menter D.G. and DuBois R.N. (2010) “HEF1 is a crucial mediator of

the proliferative effects of prostaglandin E2 on colon cancer cells,” Cancer Res. 70, 824-831.

128. Speirs C., Jernigan K.K., Kim S.H., Cha Y.I., Lin F., Sepich D.S., DuBois R.N., Lee E. and Solnica-Krezel L. (2010) “Prostaglandin signaling stimulates gastrulation movements by limiting cell adhesion through Snail stabilization,” Development, 137, 1327-1337.

129. Kim S.H., Xia D., Kim S.W., Holla V., Menter D.G .and DuBois R.N. (2010) “Human enhancer of

filamentation-1 is a mediator of hypoxia-inducible factor-1 alpha- mediated migration in colorectal carcinoma cells,” Cancer Res. 70, 4054-4063.

130. Holla V.R., Wu H., Shi Q., Menter D.G. and DuBois R.N. (2011) “Nuclear Orphan Receptor

NR4A2 modulates fatty acid oxidation pathways in colorectal cancer,” J. Biol.Chem. 286, 30003-30009. [Epub 2011 Jul 10]

131. Wang D., Ning W., Xie D., Guo L. and DuBois R.N. (2012) “Peroxisome Activated Receptor delta confers resistance to PPAR gamma-induced apoptosis in colorectal cancer cells,” Oncogene 31, 1013-1023.

132. Kim S.H., Park Y.H, Kim S.W., Lee J.S., Wang D. and DuBois R.N. (2011) “ANGPTL4 induction

by Prostaglandin E2 under hypoxic conditions promotes colorectal carcinogenesis,” Cancer Res. 71, 7010-7020.

133. Ding Q., Chang C.J., Xie X., Xia W., Yang J.Y., Wang S.C., Wang Y., Xia J., Chen L., Cai C., Li

H., Yen C.J., Kuo H.P., Lee D.F., Lang J., Huo L., Cheng X., Chen Y.J., Li C.W., Jeng L.B., Hsu J.L., Li L.Y., Tan A., Curley S.A., Ellis L.M., DuBois R.N., Hung M.C. (2011) “APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis,” J. Clin Invest. 121, 4526-4536.

134. Xia D., Wang D., Kim S.H., Katoh H., DuBois R.N., (2012) “Prostaglandin E2 promotes intestinal

tumor growth via DNA methylation,” Nature Medicine, 18, 224-226.

10-27-12 /revised 26

135. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin G, Wang D, DuBois RN, Hawk ET, Wu X, (2012) “Genetic variations in microRNA-related genes as predictors of outcomes in colorectal adenocarcinoma patients,” Clinical Cancer Res, 18, 3982-3991.

136. Charro C, Holla V, Arumugam T, Hwang R, Yang P, Lin J, DuBois RN, Menter DG, Logsdon CD,

Ramachandran V, (2012) “Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor,” Pancreas, [Epub ahead of print PMID 23090667].

137. Ross W, Lynch P, Raju P, Rodriguez A, Burke T, Hafemeister L, Hawk E, Wu X, DuBois RN,

Mishra L, (2012) “Biomarkers, bundled payments, and colorectal cancer care,” Genes Cancer, 3, 16-22.

Book Chapters 1. DuBois R.N., John M.E., Waterman M.R., West S.B., and Lu A.Y.H., “Induction of Hepatic Cytochrome P-450: Study of the Molecular Events Following Phenobarbital Administration to Rats,” (1980) Biochemistry Biophysics and Regulation of Cytochrome P-450, (J.A. Gustaffsson, J. Carlstedt-Duke, A. Mode, & J. Rafter, Eds.) 397-404, Developments in Biochemistry, Vol. 13, Elsevier, Amsterdam. 2. DuBois R.N., John M.E., Simpson E.R., Waterman M.R., and Lambeth J.D.,(1980) “Study of Regulation by ACTH of Mitochondrial Enzymes Involved in Cholesterol Side Chain Cleavage,” Biochemistry Biophysics and Regulation of Cytochrome P-450, (J.A. Gustaffsson, J. Carlstedt-Duke, A. Mode, & J. Rafter, Eds.) 515-518, Developments in Biochemistry, Vol. 13, Elsevier, Amsterdam.

3. DuBois R.N., Waterman M.R., West S.B., and Lu A.Y.H. (1980) “Induction of Cytochrome P-450 in Rat Liver,” Microsomes, Drug Oxidations, and Chemical Carcinogenesis, (M.J. Coon, A.H. Conney, R.W. Estabrook, H.V. Gelboin, J.R. O'Brian, Eds.) 603-606, Academic Press, New York.

4. Nathans D., Christy B.A., DuBois R.N., Lanahan A., Sanders L.K., and Nakabeppu Y. (1991) “Transcription Factors Induced by Growth Signaling Agents.” CSH Origins of Human Cancer: A comprehensive review, 353-364, Cold Spring Harbor Press.

5. Russell W.E. and DuBois R.N. (1994) “The Regulation of Liver Growth and Regeneration,” Liver Disease in Children, (F. Suchy, Ed.) 1st Edition, pp 11-30, Mosby Year Book.

6. DuBois R.N., Eberhart C.E. and Williams C.S. (1996) “Introduction to Eicosanoids and the Gastroenteric Tract,” Gastroenterology Clinics of North America, (R. DuBois & F. Giardiello, Eds.) 25, 267-277. 7. DuBois R.N., Giardiello F.G., Smalley W.E. (1996) “NSAIDs, Eicosanoids and Colorectal Cancer Prevention,” (Ed. R. Boland) Gastroenterology Clinics of North America, 25, 773-788.

8. DuBois R.N., Radhika, A., Shao J., Tsujii M., Sheng H., Kobyashi O., Beauchamp R.D. and Williams C.S. (1996) “Cyclooxygenase-2 and intestinal cancer,” (Eds. N. Bazan & J. Vane) New Targets of Inflammation: Inhibitors of COX-2 or adhesion molecules, 125-130, Kluwer academic publishers, Lancaster, UK.

9. DuBois R.N., Tsujii M., Morrow J., Awad J., Roberts L., and Bishop P.(1997) “Eicosanoid production and growth regulation in rat intestinal epithelial cells,” (Eds. K. Honn, S. Nigam & L. Marnett) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 2, Volume 400A, 487-493, Plenum Press, New York & London.

10. Sheng G.H., Shao J., Sheng H., Sheng G.C., Hooton E.B., Kirkland S.C., Isakson P., Beauchamp R.D., DuBois R.N. (1997) “Inhibition of intestinal tumor cell growth via cyclooxygenase-2 inhibition,” 15th Symposium on the Regulation and Disturbances of Gastrointestinal Function, Excerpta Medica, Ltd., Tokyo, Japan, Vol 15, 3-15.

10-27-12 /revised 27

11. DuBois R.N., Sheng H., Shao J., Kobyashi O., Williams C.S. and Beauchamp R.D. (1998) “Inhibition of intestinal tumorigenesis via selective inhibition of COX-2,” (Eds. J. Botting & J. Vane) Selective COX-2 Inhibitors, 67-72, Kluwer academic publishers, Lancaster, UK.

12. DuBois R.N., Myers, D. and Beauchamp, R. D. (1998) “Growth Inhibitory Signals and Liver Regeneration: The TGFβ Superfamily,” Liver Growth and Regeneration, (Strain, A. & Diehl, A.M., Eds.) Chapman & Hall, London, England, ISBN 0412712601. 13. Goldman A.P., Williams C.S., Lamps L.W., Williams V.P., Pairet M., Morrow J.D. and DuBois R.N. (1998) “Meloxicam inhibits the growth of colorectal cancer cells (Eds. J. Botting & J. Vane) Clinical Applications for Selective COX-2 Inhibitors, Kluwer academic publishers, Lancaster, UK, 141-148, ISBN 0953403904.

14. Shattuck-Brandt R. and DuBois R.N. (1999) “The molecular basis for colorectal carcinogenesis,” Current Opinion in Gastroenterology, 15, 3-7, ISSN 0267-1379.

15. Williams C.S., Shattuck-Brandt R.L. and DuBois R.N. (1999) "The role of COX-2 in Intestinal Cancer, "

(Eds. J. Bradlow, J. Fishman and M. Osborne) Cancer Prevention: Novel Nutrient and Pharmaceutical Developments, Annals of the New York Academy of Sciences, 889, 72-83, ISBN 1-57331-198-7.

16. Watson A.J., Hawk E. and DuBois R.N. (2003) “Chemoprevention of colorectal cancer,” (Eds. A.

Rustgi and J. Crawford) Gastrointestinal Cancers, A companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, Harcourt Press, pp 421-427.

17. Stack E. and DuBois R.N. (2001) “Role of cyclooxygenase inhibitors for prevention of colorectal

cancer,” (Ed. J. Scheiman) Gastroenterology Clinics of North America 30, 1001-1010. 18. Kandil H. and DuBois R.N. (2001) “Cyclooxygnease-2 (COX-2) expression by Western blotting,” (Ed.

Steven M. Powell) Colorectal Cancer: Methods and Protocols (pps 205-211), Methods in Molecular Medicine, Humana Press ISSN 0-89603-767-3.

19. Gupta R.A. and DuBois R.N. (2002) “Cyclooxygenase inhibitors and colorectal cancer,” (Eds. V.T.

DeVita, Jr., S. Hellman and S. Rosenberg) Cancer Discovery and Development, (pps 159-169) Jones and Bartlett Publishers, ISBN 0-7637-2063-1.

20. Gupta R.A. and DuBois R.N. (2003) “Cyclooxygenase-2, Prostaglandins and Colorectal

Carcinogenesis,” (Ed. Randall E. Harris) Progress in Oncology 2002, (pps 158-170) Humana Press, ISBN 1-58829-010-7.

21. DuBois R.N. (2003) “Large and Small Bowel Neoplasms,” (Eds. Goldman & Ausiello) Cecil’s Textbook

of Medicine, 22nd Edition, (pps 1211-1220) Saunders, ISBN 0-7216-9652-X.

22. DuBois R.N. (2004) “Cyclooxygenase-2 inhibitors and colorectal cancer prevention,” (Eds. Kelloff, Hawk and Sigman) Cancer Chemoprevention, Vol I, (pps 107-114) Humana Press, ISBN 1-58829-076-X.

23. Backlund M.G., Mann J.R., Wang D. and DuBois RN (2006) “Ras up-regulation of COX-2,” Methods

in Enzymology, Vol 407, Regulators of Effectors of Small GTPases: Ras Family (Eds Balch, Der, Hall) pps 401-409, Elsevier/Academic Press, ISBN-10: 0-12-182812-3.

24. DuBois R.N. (2006) “Large and Small Bowel Neoplasms,” (Eds. Goldman & Ausiello) Cecil’s Textbook

of Medicine, 23nd Edition.

25. Wang D. and DuBois R.N. (2010) “Therapeutic potential of peroxisome proliferator activated receptors in chronic inflammation and colorectal cancer,” Gastroenterology Clinics of North America, 39, 697-707.

10-27-12 /revised 28

Reviews 1. Barnard J.A., Beauchamp R.D., DuBois R.N. and Coffey R.J. (1995) “Epidermal Growth Factor-Related Peptides and their Relevance to Gastrointestinal Pathophysiology,” Gastroenterology, 108, 564-580.

2. Eberhart C.E. and DuBois R.N. (1995) “Eicosanoids and the Gastrointestinal Tract,” Gastroenterology, 108, 285-301.

3. Coffey R.J., Romano M. and DuBois R.N. (1995) "Roles of TGFα in Gastric Physiology and Pathophysiology." (A. Terano, Ed.) Proceedings from the 2nd Annual meeting on Molecular Biological Approaches to Peptic Ulcer Disease, Medical Tribune, Inc. Tokyo Japan, pp 27-30. 4. Williams C.S., and DuBois R.N. (1996). “Prostaglandin Endoperoxide Synthase: Why Two Isoforms?” American Journal of Physiology, 270, G393-G400. 5. Beauchamp R.D., Peeler M. and DuBois R.N. (1996) “Management of Colorectal Polyps: A Review.” Current Opinion in Gastroenterology, 12, 12-17.

6. DuBois R.N. and Smalley W. (1996) “Cyclooxygenase, NSAIDs and Colorectal Cancer,” Journal of Gastroenterology, 31, 898-906.

7. Smalley W. and DuBois R.N. (1997) “Colorectal cancer and non steroidal anti-inflammatory drugs,” (T. August, M.W. Anders, F Murad, and J.T. Coyle Eds.) Advances in Pharmacology, 39, 1-20.

8. Smith B. and DuBois R.N. (1997) “Current Concepts in Colorectal Cancer Prevention,” Comprehensive Therapy, 23, 184-189. 9. DuBois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., van de Putte L.B., Lipsky P.E. (1998) “Cyclooxygenase in Biology and Disease,” FASEB J. 12, 1063-1073. 10. Williams C.S., Shattuck-Brandt R.L. and DuBois R.N. (1999) “The role of COX-2 in intestinal Cancer,” Expert Opinion on Investigational Drugs 8, 1-12. 11. Shattuck-Brandt R.L. and DuBois R.N. (1999) “The molecular basis of colorectal carcinogenesis,” Current Opinion in Gastroenterology 15, 3-8. 12. Williams C.S., Mann M. and DuBois R.N. (1999) "The role of cyclooxygenases in inflammation, cancer

and development," Oncogene, 18, 7908-7916. 13. DuBois, R.N. (1999) "Cyclooxygenase-2 and colorectal cancer," Gastroenterology International 12,

182-185. 14. DuBois, R.N. (1999) "Colorectal Cancer: Identifying the high-risk patient," Women's Health in Primary

Care 2, 958-967. 15. Williams C., Shattuck-Brandt R.L. and DuBois R.N. (1999) "The role of COX-2 in intestinal cancer,"

Ann. N.Y. Acad. Sci. 889, 72-83. 16. Arber N. and DuBois R.N. (1999) "Nonsteroidal anti-inflammatory drugs and prevention of colorectal

cancer," Curr. Gastroenterol. Rep. 1, 441-448. 17. DuBois, R.N. (2000) "Cyclooxygenase--a target for colon cancer prevention," Aliment. Pharmacol.

Ther. 14, 1-4.

18. Krause W. and DuBois, R.N. (2000) "Eicosanoids and the large intestine," Prostaglandins and other Lipid Mediators 61, 145-161.

10-27-12 /revised 29

19. Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, Buttgereit F, Cannon GW, Catella-Lawson F, Crofford LJ, Doherty M, Dougados M, DuBois RN, Froelich J, Garcia Rodriguez LA, Gibofsky A, Hernandez-Diaz S, Hochberg MC, Krause A, Liang MH, Machold K, Peloso PM, Raisz LG, Schayes B, Scheiman JM, Simon LS, Smolen J (2000) "Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice," J. Rheumatol 27, 1338-1340.

20. Gupta R.A. and DuBois R.N. (2000) "Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer" Ann N Y Acad Sci. 910, 196-204.

21. Lipsky P.E., Brooks P., Crofford L.J., DuBois R.N., Graham D., Simon L.S., van de Putte L.B., Abramson S.B. (2000) "Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease," Arch Intern Med 160, 913-920.

22. Gupta R. A. and DuBois R.N. (2000) "Combination of Agents Appear Advantageous for Cancer

Prevention," Nature Medicine 6, 974-975.

23. DuBois R.N. and Mann M. (2001) “Cyclooxygenase-2 and colon carcinogenesis,” The Regulatory Peptide Letter 4, 60-63.

24. Stack E. and DuBois R.N. (2001) “Regulation of Cyclooxygenase-2,” Bailliere’s Best Practice and

Research: Clinical Gastroenterology 15, 787-800. 25. Gupta R. A. and DuBois R. N. (2001) “Colorectal cancer and the cyclooxygenase pathway,” Nature

Reviews Cancer 1, 11-21. 26. Krause W.F. and DuBois R. N. (2001) “Colorectal cancer and cyclooxygenase,” Clinical

Colorectal Cancer 1, 47-54. 27. Turini M. and DuBois R. N. (2002) “Cyclooxygenase-2: A therapeutic target,” Annual Reviews of

Medicine, 53, 35-57. 28. Marnett L. and DuBois R. N. (2002) “COX-2: A target for colon cancer prevention,” Annual

Reviews of Pharmacology and Toxicology, 42, 55-80. 29. Gupta R.A. and DuBois R. N. (2002) “Controversy: PPARγ as a target for treatment of colorectal

cancer,” Am. J. Phys. (GI and Liver), 283, G266-G269. 30. Turini M. and DuBois R. N. (2002) “Primary prevention: phytoprevention and chemoprevention of

colorectal cancer,” Hematol. Oncol. North Am. 16, 811-840.

31. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, Garcia Rodriguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Williams GH (2002) “Controversies in COX-2 selective inhibition,” J. Rheumatol. 29, 1501-1510.

32. DuBois RN (2003) “Cyclooxygenase-2 and colorectal cancer,” Prog Exp Tumor Res. 37,124-137.

33. Crosby CG and DuBois RN (2003) “The cyclooxygenase-2 pathway as a target for treatment or

prevention of cancer,” Expert Opin Emerg Drugs 8, 1-7.

34. Brown JR and DuBois RN (2004) “Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture,” Chest 125 (5 Supp) 134S-140S.

35. Wang D. and DuBois RN (2004) “Cyclooxygenase-2: A potential target in breast cancer,” Semin

Oncol 31 (1 Supp 3) 64-73.

36. Brown JR and DuBois RN (2004) “Cyclooxygenase-2 as a target in lung cancer,” Clin Cancer Res 10 (12 Pt 2) 4266s-4269s.

10-27-12 /revised 30

37. Koehne CH and DuBois RN (2004) “COX-2 inhibition and colorectal cancer,” Semin Oncol 31 (Suppl 7) 12-21.

38. Mann JR and DuBois RN (2004) “Cyclooxygenase-2 and gastrointestinal cancer,” Cancer Journal

10, 145-152.

39. Wang D., Mann JR and DuBois RN (2004) “WNT and Cyclooxygenase-2 cross-talk accelerates adenoma growth (2004) Cell Cycle 3, 1512-1515.

40. Dannenberg AJ. Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxygenase-2 and

epidermal growth factor receptor, pharmacologic targets for chemoprevention, J. Clin. Oncol. 23, 254-266.

41. Wang D., Mann JR and DuBois RN (2005) “The role of prostaglandins and other eicosanoids in

the gastrointestinal tract,” Gastroenterology 128, 1445-1461.

42. Wang D, DuBois RN (2005) “Prostaglandins and cancer.” Gut 55, 115-122. [Epub: Aug 23]

43. Peek RM, Mohla S, DuBois RN (2005) “Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting.” Cancer Res. 65, 8583-8586.

44. Backlund MG, Mann JR, DuBois RN (2005) “Mechanisms for the prevention of gastrointestinal

cancer: the role of prostaglandin E2.” Oncology, 69 Suppl 1:28-32.

45. Mann JR, Backlund MG, DuBois RN (2005) “Mechanisms of disease: Inflammatory mediators and cancer prevention.” Nat Clin Pract Oncol. 22, 202-210.

46. Cha YI, Solnica-Krezel L and DuBois RN (2006) “Fishing for prostanoids: Deciphering the

developmental functions of cyclooxygenase-derived prostaglandins,” Developmental Biology 289, 263-272.

47. Buchanan FG and DuBois RN (2006) “Connecting COX-2 and Wnt in Cancer,” Cancer Cell 9, 6-8.

48. Buchanan FG and DuBois RN (2006) “Emerging roles of β-arrestins,” Cell Cycle 5, 2060-2063.

49. Cha Y and DuBois RN (2007) “NSAIDs and cancer prevention: Targets downstream of COX-2,” Ann

Rev Med 58, 239-252. [Epub 2006 Nov] 50. Wang D and DuBois RN (2007) “Inflammatory mediators and nuclear receptor signaling in colorectal

cancer,” Cell Cycle 6, 682-685.

51. Wang D and DuBois RN (2007) “Measurement of eicosanoids in cancer tissues,” Methods Enzymol. 433:27-50.

52. Wang D and DuBois RN (2008) “Peroxisome proliferator-activated receptors and progression of

colorectal cancer,” PPAR Res. 2008, PMID 18551185

53. Wang D and DuBois RN (2008) “Pro-inflammatory prostaglandins and progression of colorectal cancer,” Cancer Lett. 267, 197-203.

54. Wang D, DuBois RN and Richmond A (2009) “The role of chemokines in intestinal inflammation and

cancer,” Curr Opin Pharmacol 9, 688-696.

55. Menter DG, Schilsky RL and DuBois RN (2010) “Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward,” Clin Cancer Res 16, 1384-1390.

56. Wang D and DuBois RN (2010) “Role of COX-2 in intestinal inflammation and colorectal cancer,”

Oncogene 29, 781-788.

10-27-12 /revised 31

57. Wang D and DuBois RN (2010) “Role of Eicosanoids (PGE2) in progression of colorectal cancer,” Nature Reviews Cancer 10, 181-193.

58. Peddareddigari V.G., Wang D. and DuBois RN (2010) “The tumor microenvironment in colorectal

carcinogenesis,” Cancer Microenviron. 3, 149-166.

59. Menter DG and DuBois RN (2012) “Prostaglandins in cancer cell adhesion, migration and invasion,” Int J Cell Biol, doi:10.1155/2012/723419: Article ID: 723419 http://www.hindawi.com/journals/ijcb/2012/723419/

60. Anderson KC and DuBois RN (2012) “Overview of the AACR Clinical and Translational Cancer

Research Think Tank meeting,” Clin Cancer Res 18, 607-611.

61. Wang D and DuBois RN (2012) “The role of anti-inflammatory drugs in colorectal cancer,” Annual Rev Med [Epub ahead of print] PMID 23020877 http://www.annualreviews.org/doi/abs/10.1146/annurev-med-112211-154330

62. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui

D, Summers B, Rodriguez A, DuBois RN, Shine, KI (2012) “Ensuring quality cancer care: a follow-up review of the Institute of Medicine’s 10 recommendations for improving the quality of cancer care in America,” Cancer 118, 2571-2582.

Editorials, Commentaries & Letters 1. DuBois, R.N. (1990) “Early Changes in Gene Expression During Liver Regeneration: What do they mean?” Hepatology 11,1079-1082. 2. DuBois R.N. (1994) “Activin A and Hepatocyte Growth Regulation,” Hepatology 19, 788-790. 3. DuBois R.N. (1994) “Can We Prevent Colorectal Cancer?,” Digestive Diseases 12, 255-258. 4. DuBois R.N. (1995) “Nonsteroidal Anti-inflammatory Drug Use and Sporadic Colorectal Adenomas,” Gastroenterology 108, 1311-1315. 5. Gupta R. and DuBois R.N. (1998) “Aspirin, NSAIDs, and Colon Cancer Prevention: Mechanisms?” Gastroenterology 114, 1095-1098. 6. DuBois R.N. (1999) "COX-2 in large bowel cancer: a one-sided story," Gut 45, 636-637. 7. Watson A.J. and DuBois R.N. (1999) "Cryptic messages in FAP," Gut 45, 795-796. 8. DuBois R.N. and Washington M.K. (2000) "COX-2 in Murine Intestinal Tumors," Gastroenterology 119, 600-602. 9. DuBois R.N. (2001) "COX-2 as a target in hepatocellular carcinoma," Clinical Cancer Res. 7, 1110-1111. 10. DuBois R. N. (2001) “New paradigms for cancer prevention,” Carcinogenesis 22, 691-692. 11. Kurie J. and DuBois R. N. (2001) “Prostaglandin E Synthase: Another enzyme in the cyclooxygenase-2 pathway driving epithelial cancer?” Clinical Cancer Res. 7, 2608-2610. 12. Slikowski M.X., and DuBois R. N. (2002) “HER-2/neu Overexpression in Colonic Malignancies,” Gastroenterology 122, 248-249. 13. DuBois R. N. (2002) “Modern Academic Medicine,” Am. J. Med. Sci. 324, 55-56. 14. DuBois R. N. (2002) “The Evolution of Modern Academic Medicine,” Gastroenterology 122, 1719. 15. Hawk E.T., Viner J.L., Dannenberg A. and DuBois R. N. (2002) “COX-2 in cancer—a player that

is defining the rules,” J. Natl. Cancer Inst. 94, 545-546. 16. Gupta R. and DuBois R. N. (2002) “Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus,” J. Natl. Cancer Inst. 94, 406-407. 17. DuBois R. N. (2002) “New agents for cancer prevention,” J. Natl. Cancer Inst. 94, 1732-1733. 18. DuBois R. N. (2002) “Modern Academic Medicine,” Am. J. Med. Sci. 324, 55-56. 19. Gupta R. A. and DuBois R.N. (2002) "Controversy: PPARγ as a target for treatment of colorectal

cancer," Am J Physiol (GI/Liver) 283, G266-269. 20. DuBois R. N. (2002) “The Evolution of Modern Academic Medicine Continues,” Gastroenterology

122, 1719. 21. DuBois R. N. (2003) “Evaluation of the entire prostaglandin biosynthetic pathway in lung cancer,”

Clinical Cancer Res. 9, 1577-1578. 22. DuBois R. N. (2003) “Leukotrienes, Inflammation and Cancer,” J. Natl. Cancer Inst., 95, 1028-

1029.

10-27-12 /revised 32

23. DuBois R. N. (2003) “Will an aspirin a day keep the endoscope away?” Gastroenterology, 125, 612-614.

24. DuBois R. N. (2003) “The physician-scientist in gastroenterology,” Gastroenterology, 125, 652.

24. Wang D. and DuBois R. N. (2004) “Cyclooxygenase-2 derived prostaglandin E2 regulates the angiogenic switch,” Proc. Natl. Acad. Sci. USA 101, 415-416.

25. DuBois R. N. (2004) “Aspirin and breast cancer prevention: The estrogen connection,” JAMA 291, 2488-2489.

26. DuBois R. N. (2004) “Disease prevention: the future is here,” Gastroenterology 127, 1289. 27. DuBois R. N. (2006) “The COX-2 Story: Is any drug completely “safe?” Gastroenterology 130, 6. 28. DuBois R. N. (2006) “Cyclooxygenase-2 selective inhibitors and prostate cancer: What is the

clinical benefit? J. Clin. Oncol. 24, 2691-2693. 29. DuBois R. N. (2006) “Cancer prevention: Strategy for the future,” Carcinogenesis 27, 1126-1127. 30. DuBois R. N. (2006) “NSAIDs and prostate cancer risk,” Cancer J. 12, 108-109. 31. DuBois R. N. (2009) “New long-term insights from the adenoma prevention trial with celecoxib,”

Cancer Prev. Res. 2, 285-287. 32. DuBois R.N. (2009) “Tailoring treatment in translational research: An interview with Raymond N.

DuBois, MD, Ph.D. by Elaine Musgrave” Clin Trans Sci 2, 178-179. 33. Wang D. and DuBois R.N. (2012) “Epoxyeicosatrienoic acids: a double-edged sword in

cardiovascular diseases and cancer” J. Clin. Research 122, 19-22. 34. Wang D. and DuBois R.N. (2012) “Associations between Obesity and Cancer: the role of Fatty

Acid Synthase,” J Natl Cancer Inst 104, 343-345. 35. Wang D. and DuBois R.N. (2012) “The Role of PGE2-aromatase in obesity-associated breast

inflammation,” Cancer Discovery 4, 308-310. 36. Wang D., Margalit O. and DuBois R.N. (2012) “Metronomic topotecan for colorectal cancer: a

promising new option,” Gut [Epub ahead of print] PMID 2268481, http://gut.bmj.com/content/early/2012/06/07/gutjnl-2012-302410.long

37. Margalit O., Wang D. and DuBois R.N. (2012) “PPARγ agonists target aromatase via both PGE2 and BRCA1,” Cancer Prev. Res. 5, 1169-1172.

Books

1. Gastroenterology Clinics of North America (1996) NSAIDs, Eicosanoids, and the Gastrointestinal Tract, (Editors: R.N. DuBois and F.G. Giardiello) 25, #2, 1-433. 2. IARC Handbook of Cancer Prevention (1997) Non-steroidal Anti-Inflammatory Drugs, Volume 1, International Agency for Research on Cancer, Working Group on the Evaluation of Cancer Preventive Agents, ISBN 92 832 3001 9. 3. Progress in Experimental Tumor Research (2003) “COX-2: A Target for Cancer Prevention and Treatment” (Editors A. Dannenberg and R.N. DuBois), S. Karger AG Publishing.

Abstracts (over 250, not shown here) Non-scientific Publications

DuBois, R.N. “Research raises hope for cure for Cancer,” The Nashville Banner, July 4, 1995 A7. DuBois, R.N. “Lifestyle changes could help stop the biggest killer of American women,” The Nashville

Banner, July 17, 1995. DuBois, R.N. “Key to surviving deadly colorectal cancer lies in early detection, prompt treatment,” The

Nashville Banner, February 2, 1996, A9. DuBois, R.N. “The Future of Biomedical Research Funding Depends on You” The Scientist, September 16,

1996. DuBois, R.N. "Colorectal cancer: It's time we talked about the previously unmentionable" The Tennessean,

February, 25, 2000.

10-27-12 /revised 33

DuBois, R.N. "We’re beating cancer, so why stall funding for research" The Tennessean, August, 28, 2006. DuBois, R.N. "Health Care Reform: So Far, Not Much of a Debate" Cancerwise Blog, The University of

Texas MD Anderson Cancer Center, September 8, 2009, http://www2.mdanderson.org/cancerwise/2009/09/health-care-reform-so-far-not-much-of-a-debate.html

DuBois, R.N. "Aspirin: Can such a commonly used drug have an impact on cancer?" Cancerwise Blog, The

University of Texas MD Anderson Cancer Center, February 24, 2010, http://www2.mdanderson.org/cancerwise/2010/02/aspirin-can-such-a-commonly-used-drug-have-an-impact-on-cancer.html

DuBois, R.N. "Celecoxib: Effective for non-melonoma skin cancer" Cancerwise Blog, The University of

Texas MD Anderson Cancer Center, December 3, 2010, http://www2.mdanderson.org/cancerwise/2010/12/celecoxib-effective-for-non-melanoma-skin-cancer.html

DuBois, R.N. "Celecoxib: Effective for non-melonoma skin cancer" Cancerwise Blog, The University of

Texas MD Anderson Cancer Center, December 3, 2010, http://www2.mdanderson.org/cancerwise/2010/12/celecoxib-effective-for-non-melanoma-skin-cancer.html

DuBois, R.N. "Institute brings hope for better cancer drugs" Cancerwise Blog, The University of Texas MD

Anderson Cancer Center, November 28, 2011, http://www2.mdanderson.org/cancerwise/2011/11/institute-to-bring-new-hope-for-better-cancer-drugs.html

DuBois, R.N. "Low dose aspirin and cancer risk" Cancer Frontline Blog, The University of Texas MD

Anderson Cancer Center, March 21, 2012, http://www2.mdanderson.org/cancerfrontline/2012/03/low-dose-aspirin-and-cancer-risk.html